Identification of new targets for the treatment of head and neck cancer: N-glycosylation gene DPAGT1 and β-catenin/CBP signaling by Alamoud, Khalid Abdulrahman M.
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2020
Identification of new targets for the



















IDENTIFICATION OF NEW TARGETS FOR THE TREATMENT OF HEAD 
AND NECK CANCER:  





KHALID ABDULRAHMAN M ALAMOUD 
 









Submitted in partial fulfillment of the requirements for the degree of 
 
Doctor of Science  









































KHALID ABDULRAHMAN ALAMOUD  
















First Reader: __________________________________________ 
 
Maria A. Kukuruzinska, Ph.D 
Professor of Molecular and Cell Biology 




Second Reader: _______________________________________ 
 
Paola Divieti Pajevic, M.D, Ph.D  
Associate Professor of Molecular and Cell Biology 
 
 
Third Reader: ______________________________________ 
 
David E. Levin, Ph.D 
Professor of Molecular and Cell Biology 




Fourth Reader: ______________________________________ 
 
Manish Bais, DVM, Ph.D 

















To my life-love, my mom, Iman Al-Zamil: because you mean the world to me and I 
owe it all to you. 
To my rock, my dad, Abdulrahman Alamoud: because your perseverance will 
continue to inspire me. 
To my siblings: Abeer, Mohammed, Maha and Abdulaziz, for their love and emotional 
support in my life. 
To my nephew, Ziyad, and the niece I’ve not yet seen, Alia, I’ve kept watching your 
videos and your tender laugh makes me happy, I’m full of love. 
To all of my great friends. 





















My deepest appreciation goes to my mentor, Prof. Maria A. Kukuruzinska. 
Your impact on me was not only limited to the scientific arena and leadership, but also 
in making me a better person by teaching me a variety of soft skills that do not exist in 
any study curriculum. Not only have you been a fantastic mentor to me, but you have 
taught me how to mentor students. You have also been an exemplary and visionary 
scientist, a great leader who has dedicated her life to the service of humanity. I 
appreciate and treasure everything you have taught me. You are definitely a wonderful 
teacher, leader, and friend. I will always be indebted for your marvelous impact on my 
life.  
 I am also grateful to my thesis committee: Prof. David E. Levin, who taught me 
how to believe in myself, by believing in me. Words can neither qualify nor quantify 
your guidance and useful advice, I will be forever grateful. Dr. Paola Divieti Pajevic, 
for her dedication, chairing the committee and insightful constructive comments. Dr. 
Manish Bias, for his valuable suggestions and warm encouragement. 
I am so lucky to collaborate with Vinay Kartha and Stefano Monti from the 
division of computational biomedicine. Their bioinformatic analyses added a broader 
molecular context to my project and increased my understanding of pathobiology of 
head and neck cancer. I would also like to extend my thanks to Prof. Maria 
Trojanowska, Dr. Ann Marie Egloff and Dr. Bob Varelas for their feedback and 






IDENTIFICATION OF NEW TARGETS FOR THE TREATMENT OF HEAD AND 
NECK CANCER:  




Boston University, Henry M. Goldman School of Dental Medicine, 2017 
Major Professor: Maria Kukuruzinska, Professor of Molecular and Cell Biology 
 
ABSTRACT   
  Head and neck squamous cell carcinoma (HNSCC) is pernicious disease with 
majority of cases presenting as oral squamous cell carcinoma (OSCC). OSCC is 
characterized by tumor heterogeneity, locoregional metastases and resistance to 
existing treatments. OSCC five-year overall survival rates are currently ~ 50 % with 
few therapeutic options available. Cancers are typically associated with dysregulated 
signaling pathways that normally have vital roles in embryonic development and 
hemostasis. We have focused on two homeostatic pathways, protein N-glycosylation 
and the canonical Wnt/β-catenin signaling, which have been shown to converge on each 
other’s activities. These pathways, when left unchecked, drive early pathogenesis 
and/or metastasis of a range of cancers, including OSCC. Aberrant activation of the 
DPAGT1 gene, encoding a key regulatory enzyme that functions at the first committed 
step in the protein N-glycosylation pathway, has been shown to be associated with 
OSCC. In OSCC, high DPAGT1 expression drives hyper-glycosylation of E-cadherin 
and loss of intercellular adhesion. Here, we provide evidence that ectopic expression of 





(EMT) by upregulation of a key transcription factor, ZEB1, and mesenchymal protein, 
vimentin, coincident with increased cell migration. In contrast, partial knockdown of 
DPAGT1 in metastatic OSCC HSC-3 cells reduced expression of the EMT markers, 
diminished cell migration and enhanced intercellular adhesion. Further, inhibition of 
the DPAGT1 enzyme, GPT, with tunicamycin interfered with orthotopic tongue tumor 
growth and metastasis in nude mice coincident with diminished expression of vimentin-
positive cells invading the tongue stroma. One mechanism responsible for increased 
DPAGT1 expression in OSCC is transcriptional activation by β-catenin. We now show 
that blocking transcriptional activity of β-catenin by interfering with its interaction with 
the cAMP-responsive element binding (CREB)-binding protein (CBP) using a small 
molecule inhibitor, ICG-001, inhibited cell proliferation and mesenchymal cell 
phenotypes in cellular models. In addition, ICG-001 abrogated tumor growth and 
metastases in zebrafish and murine models. Microarray analyses of ICG-001 gene 
expression signature revealed inhibition of genes involved in cell proliferation, 
survival, stemness, as well as N-glycosylation, but upregulation of genes functioning 
in cell adhesion and cell polarity. Importantly, the ICG-001 inhibition-associated 
transcriptional signature tracked with advanced tumor grade and poor survival in 
human patients. Our studies provide the first evidence that aberrant activation of 
DPAGT1 and β-catenin signaling promotes aggressive traits of OSCC cells and suggest 
that targeting the β-catenin/CBP interaction in the nucleus may provide an effective 
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OSCC accounts for the majority of head and neck cancers and ranks among the 
most aggressive malignancies (1, 2). Despite significant progress in the characterization 
of genomic alterations and identification of dysregulated signaling pathways, the 
molecular mechanisms underlying OSCC pathogenesis and resistance to therapeutic 
interventions remain poorly understood (1, 3-6). Thus, decoding how oral epithelia lose 
control of homeostasis and acquire proliferative and survival advantage and how they 
adopt migratory and invasive phenotypes is critical for the identification of new targets 
for improved and effective OSCC therapies. 
Modification of proteins at the asparagine residues with oligosaccharide 
structures, N-glycans, henceforth referred to as N-glycosylation, plays critical roles in 
tissue development and homeostasis by affecting diverse cellular functions (7-10). In 
addition to the well acknowledged roles of N-glycans in protein folding, activity, 
targeting, and secretion, N-glycosylation influences protein-protein interactions and 
cellular signaling events (7, 11-14). N-glycosylation has been shown to be 
indispensable for development, and its dysregulation has been linked to various 
diseases, including cancer (9, 15, 16). Indeed, changes in N-glycan structures have been 
shown to accompany tumor development and progression, with a several N-
glycosylation genes identified as key players in carcinoma biology (17, 18).  
The N-glycosylation pathway is initiated in the endoplasmic reticulum (ER) by 
the DPAGT1 gene with essential roles in  normal development, as its knockout leads 
to pre-implantation lethality in mice (9) . DPAGT1 encodes the dolichol phosphate-





first step in lipid-linked oligosaccharide (LLO) synthesis in the ER that involves the 
transfer of GlcNAc-P from UDP-GlcNAc to dolichol-P to produce dolichol-PP-
GlcNAc. This enzyme functions at a major control point for the overall N-glycosylation 
pathway, and changes in its expression are coordinated with the expression of 
downstream N-glycosylation genes in the ER and in the Golgi (19) (Figure1).  
 
Figure 1. Simplified scheme of the N-glycosylation pathway. N-Glycosylation is 
initiated in the endoplasmic reticulum (ER) by the GPT, encoded by the DPAGT1gene. 
GPT catalyzes the transfer of GlcNAc from UDP-GlcNAc to dolichol-phosphate to 
produce dolichol-PP-GlcNAc, which is the first step in the synthesis of LLO precursor. 
Subsequently, LLO is transferred co-translationally to newly synthesized polypeptides. 
After initial processing steps in the ER, glycoproteins transitto the Golgi, where N-
glycans are further modified, giving rise to mature N-glycoproteins modified with 
oligosaccharides ranging from high mannose/hybrid to complex. 
 
N-glycosylation is a ubiquitous process affecting more than 40% of cellular 
proteins, where the effects of N-glycans on protein function range from negligible to 
profound.  One major downstream effector of N-glycosylation is E-cadherin, a calcium-
dependent epithelial cell-cell adhesion receptor. E-cadherin is a single-span 





The extracellular domains of E-cadherin form calcium-dependent lateral dimers that 
interact with E-cadherin’s lateral dimers on adjacent cells. The juxtamembrane region 
of the cytoplasmic tail of E-cadherin interacts with p120 catenin, while the C-terminal 
domain binds either β-catenin or γ−catenins.  E-cadherin-bound β-catenin (or γ−catenin) 
recruit α-catenin which functions in linking the cadherin/catenin complexes to the actin 
cytoskeleton. These E-cadherin/catenin complexes represent immature, nascent 
structures that further interact with numerous actin binding and cross-linking proteins, 
signaling molecules and myosin to form adherens junctions (AJs) that ultimately 
establish stable adhesion belts required for the acquisition of mature tissue architecture 
(20-22) .  These mature AJs  (23)  that play pivotal roles in cell polarity, cell-surface 
mechanics, cell migration, cell survival, cell differentiation (20, 24-27), as well as in 
prevention of tumor spread (28).  
N-glycosylation of E-cadherin has been shown to regulate cell-cell adhesion (12, 
28-30). We and others have reported that complex oligosaccharides that modify E-
cadherin in proliferating cells inhibit adhesion, whereas high-mannose/hybrid structure 
promote the formation of mature adherens junctions in dense cultures (12, 30) . We 
have shown that DPAGT1 is a regulator of the N-glycosylation status of E-cadherin 
(31, 32). Increased expression of DPAGT1 is associated with OSCC and loss of E-
cadherin adhesion, whereas hypo-glycosylation of E-cadherin coincides with 
differentiation and loss of β-catenin and γ−catenin from the nucleus. These effects of 
DPAGT1 on E-cadherin function account for some of its oncogenic roles in a number 
of carcinomas. Indeed, inhibition of GPT with its specific antibiotic inhibitor, 
tunicamycin, has been shown to interfere with tumorigenesis and to have a synthetic 





Given the association of DPAGT1 with reduced E-cadherin adhesion in OSCC, 
and given that E-cadherin functions as a tumor suppressor, we carried out studies to 
further define oncogenic roles of DPAGT1 and N-glycosylation in OSCC. Our studies 
included defining association between DPAGT1 expression/N-glycosylation status and 
OSCC cells’ ability to drive aggressive phenotypes in cellular and murine models. 
Further, we carried out analysis of transcriptional signatures of DPAGT1 knockdown 
in indolent and metastatic OSCC cells and found that DPAGT1 impacts genes that 
function in promoting EMT, stemness, extracellular matrix remodeling and tumor 
microenvironment. Further, interrogation of The Cancer Genome Atlas (TCGA) for 
OSCC validated association of DPAGT1 activity with the EMT transcription factors, 
oncogenic pathways, cell adhesion, extracellular matrix remodeling and immune 
response. Moreover, it confirmed that upregulated DPAGT1 expression accompanied 
transition from non-malignant (G0) to malignant (G1) OSCC tumor grade. 
In addition to regulating E-cadherin-mediated cell-cell adhesion and its tumor 
suppressive function, N-glycosylation interacts with β-catenin/Wnt signaling, where 
the latter has pivotal effects on cancer development and progression (10, 38-41). In our 
earlier studies, we reported that in some cellular contexts, DPAGT1/protein N-
glycosylation interact with Wnt/β-catenin via a positive feedback mechanism (42), in 
which  the DPAGT1 gene is a transcriptional target of Wnt/β-catenin signaling with 
increased β- and γ−catenins levels correlating with their greater occupancy at the 
DPAGT1 promoter (19) . 
Importantly, increased DPAGT1 expression promotes N-glycosylation and 
activities of Wnt components, including Wnt3a and LRP5/6, giving rise to upregulation 





overexpressed and functions in an unchecked positive feedback loop with Wnt/β-
catenin signaling., DPAGT1-driven increased N-glycosylation of E-cadherin abolishes 
the ability of E-cadherin to attenuate Wnt/β-catenin and DPGAT1 expression via a 
negative feedback mechanism (10, 19, 43) (Figure2).  
 
 
Figure 2. Signaling network of DPAGT1, canonical Wnt signaling and E-cadherin. Canonical 
Wnt signaling activates DPAGT1 expression and protein N-glycosylation, leading to 
extensive N-glycosylation of E-cadherin and weak intercellular adhesion. In OSCC, 
this positive feedback loop between Wnt signaling and DPAGT1 is amplified, in part, 
by diminished expression of DKK-1, a canonical Wnt inhibitor. Furthermore, extensive 
N-glycosylation of E-cadherin prevents it from depleting nuclear β- and γ-catenins, 
allowing the positive feedback between Wnt and DPAGT1 to operate without controls. 
 
    
Numerous studies have shown that loss of E-cadherin-mediated cell-cell 
adhesion can promote β-catenin-mediated signaling (10, 21, 44-47). Thus,  unchecked 
amplification of the DPAGT1-Wnt/β-catenin feedback loop and loss of E-cadherin 
adhesion lead to the activation of a key downstream pro-tumorigenic pathway, the non-
canonical Wnt/planar cell polarity (Wnt/PCP) pathway, via increases in the expression 





DPAGT1 has been also implicated in EMT, a key process underlying the 
progression of carcinomas. Both Wnt/β-catenin signaling and E-cadherin-mediated 
adhesion play central roles in these processes. Canonical Wnt and E-cadherin share a 
key mediator, β-catenin, which has an essential structural role in E-cadherin-mediated 
cell-cell adhesion, in addition to being a central transcriptional effector of canonical 
Wnt signaling (43) .   
A common feature of cancer cells is their ability to highjack key homeostatic 
pathways and to subvert their activities toward processes that facilitate their adaption 
to new microenvironments. As a central homeostatic pathway, Wnt/β-catenin signaling 
plays pivotal roles in development, tissue injury and regeneration, and in the 
maintenance of somatic stem cell niches in multiple tissue types (49-52). Not 
surprisingly, Wnt/β-catenin signaling is one of the key drivers implicated in OSCC 
pathogenesis (38-40) Activation of canonical Wnt signaling involves the binding of 
Wnt ligands to LRP/Frizzled receptor complexes, triggering intracellular signaling 
cascades that prevent the phosphorylation of the transcriptional regulator, β-catenin by 
the inhibition of glycogen synthase kinase 3β (GSK3β) activity which plays a central 
role in promoting nuclear accumulation of β-catenin and leading to its  association with 
T-cell factor/lymphoid enhancer-binding factor (Tcf/Lef) to activate transcription of 
target genes, including EMT transcription factors responsible for transcriptional 







Figure 3. Wnt signaling pathway (A). In inactive canonical Wnt signaling, absence of 
Wnt ligands leads to the phosphorylation of β-catenin by the destruction complex, 
which contains the scaffold protein Axin, APC and the kinases GSK3β. β-catenin is 
phosphorylated by GSK3β and ubiquitinated by β-TrCP then targeted for proteasomal 







Figure 4. (B). The canonical Wnt signaling pathway is activated upon binding of 
secreted Wnt ligands to Frizzled receptors and LRP co-receptors. The Dishevelled 
polymers inactivate the destruction complex. This results in stabilization and 





forms an active complex with LEF (lymphoid enhancer factor) and TCF (T-cell factor) 
proteins by recruitment of cAMP-response element-binding (CREB)-binding protein 




Under normal conditions of development and homeostasis, the transcriptional 
activity of β-catenin is subject to negative regulatory controls, with Dickkopf-1 (DKK-
1) playing a major inhibitory role. We and others have reported that DKK-1 is 
undetectable in OSCC, providing one potential mechanisms for its intrinsically high 
activity in this malignancy (45, 53, 56) . In addition, persistent activation of β-catenin 
signaling in OSCC can result from somatic inactivating mutations in the upstream 
regulatory components that converge on the Wnt/β-catenin pathway, such as Notch1, 
FAT1 and Ajuba (6, 57-60), (61-64). 
Recent findings suggest that cellular heterogeneity within tumors is responsible 
to resistance to therapies, cancer progression and recurrence, and that it reflects, in part, 
the presence of stem cell-like niches. The Wnt/β-catenin signaling cascade has been 
shown to promote aggressive cancer phenotypes through the maintenance of cancer 
stem cells (CSCs) and to contribute to resistance to current therapies (65, 66). CSCs 
exhibit the ability to self-renew, are capable of seeding tumors at low numbers in mouse 
xenografts and driving tumor progression to invasion and metastasis. These CSCs are 
highly resistant to conventional therapies and are believed to be linked to cancer cell 
expansion, locoregional spread with lymph node metastasis, and tumor recurrence 
following treatment (67-70).  During the past decade, CSCs have been identified in 
HNSCC by the presence of a primitive cell surface marker cluster of differentiation 44+ 





catenin transcriptional activity were shown to express, in addition to CD44+, immature 
markers CD24+ and CD29+ (74). These markers have provided a useful tool for the 
isolation and characterization of subpopulations of OSCC CSCs. Thus, targeting β-
catenin has the potential to inhibit and eliminate treatment-resistant CSCs, and to 
intercept this malignancy. Nonetheless, despite compelling evidence that β-catenin 
plays important roles in OSCC, targeting β-catenin nuclear activity has not been 
extensively explored for the treatment of this malignancy (75, 76). 
  
The important roles played by Wnt/β-catenin signaling in cancers prompted the 
development of targeted agents, including a number of protein and small molecule 
inhibitors (77-79) . Initially, these inhibitors targeted primarily upstream components 
of the Wnt/β-catenin pathway and were accompanied by deleterious functional 
consequences. In contrast, blocking nuclear β-catenin activity that specifically impacts 
a subset of its transcriptional targets has demonstrated more promise. Of particular 
interest is a small molecule inhibitor that preferentially blocks the interaction between 
β-catenin and CBP in the nucleus (Figure 3). First identified for its anti-tumorigenic 
effects in pre-clinical models of colorectal cancer (80), ICG-001 has been shown to 
have a beneficial role in interfering with multiple diseases (81-84). Nonetheless, little 
is known about the molecular and cellular mechanisms targeted by ICG-001 in OSCC. 
To identify an effective strategy to target treatment-resistant OSCC cells and to 
interfere with overall tumor growth and metastasis, we have focused on targeting β-
catenin/CBP transcriptional activity with ICG-001 using a combination of in vitro and 





datasets derived from TCGA. We provide evidence that inhibition of β-catenin/CBP 
nuclear activity in a panel of OSCC cell lines by ICG-001 interferes with cell 
proliferation and enhances junctional membrane localization of β-catenin concomitant 
with a loss of mesenchymal phenotype in favor of differentiated epithelial morphology. 
In response to ICG-001, patient-derived OSCC tumor xenografts in nude mice display 
reduced growth and loss of invasive characteristics while acquiring prominent 
junctional E-cadherin and β-catenin localization. Further, ICG-001 effectively and 
preferentially inhibited rapid tumor metastases of aggressive subpopulations of OSCC 
cells in zebrafish embryos. Importantly, we demonstrate the association between ICG-
001 treatment signatures with changes in N-glycosylation activates and poor clinical 
outcomes in human OSCC patients. Lastly, our query of ICG-001 treatment signature 
against thousands of other annotated treatment signatures available in the 
ConnectivityMap (https://www.broadinstitute.org/connectivity-map-cmap) to assess if 
they have mimicking or antagonizing effects across multiple cellular contexts, revealed 
the GPT inhibitor, tunicamycin, as one of the top ranked compounds with ICG-001 
overlapping activities. This provided support that ICG-001 targeted genes that impacted 
DPAGT1 and N-glycosylation. Collectively, our studies align DPAGT1/N-
glycosylation and β-catenin/CBP transcriptional activity with OSCC aggressive traits 
and suggest that targeting nuclear β-catenin-CBP interaction represents a potential 








Section 1: N-glycosylation in HNSCC 
 
MATERIALS AND METHODS 
Reagents 
 
Monoclonal antibodies to human E-cadherin, α-catenin, β-catenin, γ-catenin, 
IQGAP1, ZO-1, and IgG isotype controls were obtained from Becton Dickenson (BD). 
Monoclonal antibodies to vinculin and pan-actin were from Upstate Biotechnology and 
Neomarkers, respectively. Rabbit polyclonal antibody to hamster DPAGT1 was 
prepared commercially (Covance Research Products). Secondary antibodies included 
goat anti-mouse and anti-rabbit IgG derivatized with either FITC or Texas red 
(Molecular Probes). 
 
Cell lines  
 
Cell lines were obtained from the following sources: human CAL27 were 
purchased from ATCC, and human HSC-3 cells were obtained from XenoTech, Japan. 
All cell lines were authenticated by short tandem repeat DMA profiling every 6 months 
either by ATCC or Genetica. Cells were grown at 37oC under 5% CO2 to 70% 
confluence in DMEM (Invitrogen) supplemented with 10% fetal bovine serum, 











Total cell lysates (TCLs) from DMSO or ICG-001-treated HSC-3 cells were 
prepared by extraction with Triton/β-octylglucoside buffer, as described (15, 85). 
Protein concentrations were determined using BCA assay (Pierce). For immunoblot 
analyses, TCL (20-30 µg of total protein) were fractionated on 7.5% SDS-PAGE, 
transferred onto polyvinylidene difluoride membranes, blocked with 5% nonfat dry 
milk, and incubated with primary antibodies to E-cadherin, β-catenin and IQGAP-1 
(BD, mouse), p-GSK3β and GSK3β (Cell Signaling, Rabbit), DPAGT1 (Covance 
Research Products, Rabbit) and GAPDH (Novus Biologicals, mouse). Protein-specific 
detection was carried out with horseradish peroxidase-labeled secondary antibodies 
conjugated to horseradish peroxidase (Bio Rad), and Enhanced Chemiluminescence 





Equal amounts of TCL from CAL27 and HSC-3 cells (300 µg) were precleared 
with IgG isotype control antibodies and 30 µl of protein G-coupled Sepharose beads 
(GE Healthcare) or protein A-coupled Agarose beads, incubated for 2 h at 4 °C with 
2.5 µg of antibodies against E-cadherin followed by incubation with protein G or A 
beads. To assure specificity, all immunoprecipitation studies routinely included IgG 
controls.  The beads were washed three times with lysis buffer (10 mM Tris–HCl, pH 
7.5, 1 mM EDTA, 1 mM EGTA and 0.5% Triton X-100), samples were eluted in 100 





Mice and Orthotopic Xenograft Models 
 
All experiments were approved by the Boston University Medical Center 
Institutional Animal Care and Use Committee.  HSC3 cells were lentivirally transduced 
with DsRed and suspended in serum-free Dulbecco’s modified eagle medium 
(DMEM). For orthotopic tongue xenografts, 0.5 × 106 cells in 40 µl of DMEM were 
injected into each tongue of two-month old nude mice (Taconic Farms, Hudson, NY) 
that were anesthetized with isoflurane. Anesthesia was administered in an induction 
chamber with 2.5% isoflurane in 100% oxygen at a flow rate of 1 L/min and then 
maintained with a 1.5% mixture at 0.5 L/min. Two days following injection, mice 
(n=16) were equally divided into two groups: vehicle (control) and tunicamycin-
treated. For tumor inhibition studies, tunicamycin was administered topically at a 
concentration of 25 µg /kg every third day into treatment-group mice via the tongue. 
Digital caliper measurements were performed at 2 – 3 day intervals to monitor the 
volumes of all tumors. Mice were imaged for DsRed protein expression on day 25 using 
an IVIS 200 system (Xenogen, Alameda, CA, USA). The fluorescence signals were 
optimized for the DsRed protein at excitation 570 and emission 620. Fluorescence 
region of interest (ROI) data were calibrated and normalized fluorescence efficiency 
(p/s/cm2/sr)/(µW/cm2) determined as per the instructions (Perkin Elmer, USA). The 
data are reported as normalized fluorescence intensity (FU) from a defined region of 
interest for oral tongue tumors or systemic metastases compared to control vehicle-







Mouse Tumor Sample Processing  
 
Tumors were harvested at sacrifice at day 25, weighed and processed for 
histology, immunohistochemistry analyses. Tumors were paraffin-embedded and 5 µm 
sections were placed on OptiPlus Positive-Charged Barrier Slides (BioGenex), 
deparaffinized, treated with Retrievit-6 Target Retrieval Solution (BioGenex), and 
processed for immunofluorescence and histological analyses (see below). 
 
IncuCyte (scratch wound assay) 
 
Cells were grown at 37oC under 5% CO2 to 70% confluence in DMEM 
(Invitrogen) supplemented with 10% fetal bovine serum, penicillin, and streptomycin. 
Cells were seeded in 24-well tissue culture dishes, incubated for 6 hours to allow them 
to adhere and spread, and cultured to confluence. Cells were then wounded using sterile 
10 µl pipette tips and imaged at 0, 6, 9 and 15 hours under a phase contrast microscope 
(10X). Three independent fields were recorded for each cell preparation, and each 
wounding assay was performed three times.  
 
Lentiviral transduction for the perturbation of DPAGT1 expression  
	
On day 0, HEK293T cells were seeded to approximately 75%~80% confluence 
in a 6-well plates in 2 mL DMEM growth medium with 10% FBS without antibiotics. 
The next day, the lentiviral transfer vector DNA (GFP, LacZ and DPAGT1), together 
with psPAX2 packaging and pMD2.G envelope plasmid DNA were combined at a ratio 
of 5 : 1.5 : 0.75, respectively into HEK293T cells. Backbone lentiviral plasmid (2 





of Lipofectamine-2000 were diluted in 0.25 ml of Opti-MEM and incubated at room 
temperature for 20 minutes followed by mixing the Lipofectamine-2000 and DNA and 
incubated for an additional 20 minutes at room temperature. The DNA-Lipofectamine-
2000 complex was added to the wells which were left in the incubator for 6 hours. The 
next day, the medium was discarded and 20% FCS DMEM (2 ml/well) were added. 
GFP expression was checked after 24 hours of transduction, with 70 -80% of cell 
expressed GFP (GFP+ cells).  On the third day, the virus was collected and aliquots 
were stored at -80oC for subsequent studies. 
CAL27 cells were maintained in DMEM (Gibco) supplemented with 10% FBS 
and 1% L-Glutamine. To partially induce DPAGT1 expression, CAL27 cells were 
transduced at 50% confluence with Lentiviral constructs bearing DPAGT1 cDNA 
(Origene) using Lipofectamine 2000 (Invitrogen) and grown at 37oC overnight. The 
next day, the media were replaced with DMEM containing penicillin and streptomycin 
and cells were allowed to grow to confluence. HSC-3 cells were maintained in DMEM 
(Gibco) supplemented with 10% FBS and 1% L-Glutamine. To partially inhibit 
DPAGT1 expression, HSC-3 cells were transduced at 50% confluence with lentivirus 
bearing DPAGT1 shRNA (Dharmacon) using Lipofectamine 2000 (Invitrogen) and 
grown at 37oC overnight. The next day, the media were replaced with DMEM 




 ChIP assays were carried out with chromatin cross-linked with 1% 
formaldehyde from CAL27 and HSC-3 cells. For tissue ChIP analyses, tissues were 





°C. The sonicated extract was immunoprecipitated, and genomic DNA was isolated 
from the complex after reverse cross-linking. The primers and the TaqMan probe 
surrounding the Wnt-responsive element were designed using the Primer Express 
program (Applied Bio-systems) and were: forward primer 5 - 
GCTTTAGAATTTACACCATCCTTCCA-3, reverse primer 5 -
AGCCAAGGTAAACACAACTCAGTTC-3 and TaqMan probe 6FAMATC GTA 
GCT TTG TTT CCGMGBNFQ. 
 
RNA isolation and RT-qPCR  
 
Total RNAs were extracted from CAL27 and HSC-3 cells using an RNeasy 
RNA isolation kit (Qiagen). Reverse transcriptase reactions for DPAGT1 were 
performed using a SuperScript first-strand synthesis system (Invitrogen) and 
SuperScript III reverse transcriptase. Reactions were carried out with ABI Prism 7300 
sequence detection PCR machine (Applied Biosystems) using TaqMan gene expression 
system, per the manufacturer’s instructions. Statistical analysis was performed using 
real time PCR from three independent RNA preparations, with each experiment 




Mouse tumor tissue sections were blocked with 10% goat serum, mouse IgG 
blocking reagent (Vector) and incubated with antibodies against vimentin (Sigma, 
mouse), DPAGT1 (Covance Research Products, Rabbit), β-catenin and E-cadherin 





and anti-rabbit IgG derivatized with either FITC or Texas red (Molecular Probes). 
Negative controls lacked primary antibodies. The slides were mounted in Vectashield 
and optical sections (0.5 µm intervals) were analyzed by confocal microscopy using an 
LSM510 Zeiss Axiovert 200M confocal microscope. To compare fluorescence 
intensities between samples, settings were fixed to the most highly-stained sample with 
all other images acquired at those settings. Images were processed with ZEN 2 and 




Mouse tumor tissues were fixed overnight in 4% paraformaldehyde in PBS and 
dehydrated. Samples were processed, embedded in paraffin and sectioned (5-µm 
thickness) and stained with hematoxylin and eosin (H&E) at the Boston University 
Medical Campus Pathology Core Facility. Digital images of stained slides were 





Analyses of gene expression signatures in response to inhibition of DPAGT1 
expression were carried out with total RNAs isolated from the HSC-3 cell line treated 
either with a control shRNA or with shRNA directed against DPAGT1 (n=3 per 
experimental group) using Human Gene 2.0 ST arrays. Affymetrix Human Gene 2.0 
ST CEL files were normalized to produce gene-level expression values using the 
implementation of the Robust Multiarray Average (RMA) (86)  in the affy package 





(88) and an Entrez Gene-specific probeset mapping (version 16.0.0) from the Molecular 
and Behavioral Neuroscience Institute (Brainarray) at the University of Michigan (89). 
Array quality was assessed by computing Relative Log Expression (RLE) and 
Normalized Unscaled Standard Error (NUSE) using the affyPLM Bioconductor 
package (version 1.34.0) (90). Principal Component Analysis (PCA) was performed 
using the prcomp function with expression values that had been normalized across all 
samples to a mean of zero and a standard deviation of one. Differential gene expression 
with respect to shRNA treatment group was assessed by performing a one-way 
ANOVA computed using the f.pvalue function in the sva package (version 3.4.0). 
Correction for multiple hypothesis testing was accomplished using the Benjamini-
Hochberg false discovery rate (FDR) (91) . All microarray analyses were performed 














DPAGT1 is associated with the EMT program in oral cancer cells 
Aberrant acquisition of mesenchymal properties has been shown to underlie 
cancer cell behavior including an attainment of “stem-like” characteristics and 
metastatic features, the hallmarks of aggressive disease. This process, termed the 
epithelial-mesenchymal transition (EMT), is a highly conserved cellular program that 
allows polarized, immotile epithelial cells to become motile mesenchymal cells. This 
involves changes in cell phenotype that include morphological changes from a 
cobblestone-like monolayer of epithelial cells with an apical-basal polarity to dispersed, 
spindle-shaped mesenchymal cells with migratory protrusions, as well as changes of 
differentiation markers from cell-cell junction proteins and cytokeratin intermediate 
filaments to vimentin filaments and fibronectin accompanied by functional changes. As 
such, EMT is an important and necessary process of tumorigenesis implicated in 
carcinoma invasion, locoregional spread and metastasis.  
Our previous studies have shown that forced expression of DPAGT1 induced 
mesenchymal changes in Madin-Darby canine kidney cells (MDCK) and primary 
human oral keratinocytes HOK cells (43). Thus, it was likely that its aberrantly high 
expression could underlie mesenchymal characteristics of oral cancer cells. We first 
examined if increased DPAGT1 expression was associated with metastatic 
characteristics of OSCC cells. For these studies, we used two human OSCC cell lines 
derived from SCC of the tongue: the CAL27 cells, shown to form non-metastatic 
tumors in nude mice, and HSC-3 cells, which generate tongue tumors that spread to the 





Comparison of cellular morphologies by light microscopy revealed that non-metastatic 
CAL27 cells had cuboidal characteristics and formed a monolayer, whereas metastatic 
HSC-3 cells displayed elongated spindle-shaped phenotypes suggesting a 
mesenchymal state (Figure 4).   
 
 
Figure 5. Cellular phenotype of CAL27 and HSC-3 cells. (Magnification, 10x) 
 
Immunofluorescence analyses further showed that both DPAGT1 and nuclear 







Figure 6.  GPT and β-catenin expression in CAL27 and HSC-3 cells. 
 
Next, to confirm that changes in DPAGT1 expression were associated with 
distinct surface presentation of N-glycans, we examined the N-glycosylation signature 
of human CAL27 and HSC-3 cells at baseline using lectins that recognize specific N-
glycan structures reflective of different cellular N-glycosylation signatures. This 
included L-phytohemagglutinin- (L-PHA)-reactive complex N-glycans, which 
characterize proliferating and tumor cells, and concavalin A (Con-A) lectin, which 
reacts with high-mannose/hybrid N-glycans that are typical of growth-arrested and 
differentiated cells. To determine CAL27 and HSC-3 lectin reactivities, we sorted cells 
with FITC-conjugated L-PHA and ConA lectins using fluorescence assisted cell sorting 
(FACS). Results showed that N-glycans decorating CAL27 cells exhibited greater 
reactivity to ConA, while HSC-3 cells had considerably greater modification of L-






Figure 7.  Immunofluorescence localization of PHA-L and ConA lectins in CAL27 and 
HSC3 cells. Increased surface expression of complex glycans in HSC3 and greater 
expression of mannose/hybrid glycans in CAL27 cells. 
 
These results suggested that DPAGT1-dependent increased modification with 
complex oligosaccharide structures was a corollary of metastatic OSCC cells. In 
addition, we examined differences in junctional stability in indolent CAL27 and 
metastatic HSC-3 cells. We have shown previously that IQGAP1, a junctional 
destabilizer, had increased expression and junctional localization in OSCC tumors. This 
was associated with destabilized cadherin junctions (15, 92) as evidenced by 
diminished interactions with α-catenin and γ−catenin. Examination of these 
components in HSC-3 cells revealed that they displayed enhanced levels of IQGAP1 
compared to CAL27 cells that correlated with reduced levels of E-cadherin (Figure 7, 
A). Also, reduced levels of E-cadherin in HSC-3 cells correlated with a lesser 
interaction of E-cadherin with γ−catenin and α−catenin in co-immunoprecipitation 







Figure 8. (A). Immunoblot of total cell lysates extracted from CAL27 and HSC-3 cells 
and analyzed with antibodies against β-catenin, IQGAP-1 and E-cadherin, with 
GAPDH as a loading control (unpaired t-test; **p<0.001). (B). Immunoblot of a co-
immunoprecipitate of E-cadherin with γ- and α-catenin from CAL27 and HSC-3 cells. 
 
Since reduced junctional stability of E-cadherin is associated with proliferative 
phenotypes, we examined the expression of a key component of the Wnt/β-catenin 
signaling pathway, GSK3β, which maintains low levels of cellular β-catenin through 
its function as a member of the destruction complex with Axin, CK1α and APC 
(Figure 3A). Notably, HSC-3 cells exhibited a greater fraction of inactive, 






Figure 9. Immunoblot of total cell lysates extracted from CAL27 and HSC-3 cells and 
analyzed with antibodies against p-GSK3β (inactive) and GSK3β (active), with 
GAPDH as a loading control (unpaired t-test; ***p<0.0001). 
 
Collectively, these data showed that the metastatic phenotypes of HSC-3 cells 
were associated, at least in part, with increased DPAGT1 expression and enhanced 
cell surface modification with complex N-glycans. Such N-glycosylation changes, in 
turn, were associated with activation of GSK3β and upregulation of β-catenin levels, 
coincident with destabilization of E-cadherin junctions.    
Given that DPAGT1 expression was associated with metastatic characteristics 
of OSCC cells (19) , we asked if DPAGT1 could drive EMT in non-metastatic CAL27 
cells. Lentiviral transduction of DPAGT1 into CAL27 cells resulted in upregulation of 







Figure 10. Immunoblot of total cell lysates extracted from empty vector (E)- and 
DPAGT1-transfected CAL27 cells and analyzed with antibodies against GPT, β-
catenin and ABC, with GAPDH as a loading control (unpaired t-test; **p<0.001, 
*p<0.01). 
 
This was associated with the induction of transcripts for ZEB1, vimentin and 
fibronectin (Figure. 10A). To confirm that DPAGT1 regulated OSCC cell plasticity, 
we inhibited DPAGT1 expression with lentivirally transduced shRNA in metastatic 
OSCC HSC-3 cells and showed that DPAGT1 knockdown inhibited ZEB1 transcript 







Figure 11. DPAGT1 expression is associated with EMT. (A). CAL27 cells transduced 
with DPAGT1 exhibited a mesenchymal phenotype associated with EMT markers’ 
expression. (B). HSC-3 cells acquired an epithelial morphology following DPAGT1 
knockdown that was associated with inhibition in EMT markers.  
 
  
DPAGT1 promotes OSCC cell migration 
 
   We have reported previously that DPAGT1 induced a promigratory and pro-
metastatic protein, CTHRC1, in OSCC cell lines and that it was associated with its 
increased abundance in human OSCC specimens (48). In addition, we showed that 
inhibition of DPAGT1 with RNAi reduced migration of CAL27 cells. To examine 
whether DPAGT1 expression levels could modulate migratory behavior of OSCC cells, 
we analyzed the rates of migration of non-metastatic CAL27 cells following lentiviral 





showed that CAL27 cells harboring DPAGT1 migrated with a 20% faster rate of 17.8 




Figure 12. DPAGT1 transduced CAL27 cells had 40-fold greater DPAGT1 mRNA 
levels (qPCR) and this correlated with a 36% increase in migration rates (unpaired t-
test; *p<0.01).  
 
Conversely, inhibition of DPAGT1 in metastatic HSC-3 cells had the opposite 
effect and reduced their migration rates. Inhibition of DPAGT1 expression with 
lentivirally-transduced shRNA reduced the rate of migration to from 64.5 µm/hr 21.3 
µm/hr (Figure 12). Further, we used a pharmacological inhibitor of GPT activity, 
tunicamycin, at a low concentration of 50 ng/ml in order to avoid induction of an 














the drug. Results showed that treatment of cells with 50 ng/ml tunicamycin was 
sufficient to inhibit HSC-3 cell migration from 64.5 µm/hr to 23.8 µm/hr (Figure 12). 
Collectively, these results showed that changes in DPAGT1 expression modulated 




Figure 13. Both DPAGT1 shRNA transduced (77% knockdown) and tunicamycin 
treated HSC-3 cells displayed reduced migration rates of 67% and 63%, respectively 



























DPAGT1 drives OSCC tumor growth, invasion and metastasis in vivo 
 
Since our data showed that DPAGT1 regulated the transition between epithelial 
and mesenchymal states and cell migration, and since both EMT and cell migration 
underlie invasive cell behavior and metastasis, we hypothesized that treatment of HSC-
3-driven tumors with tunicamycin, a specific inhibitor of GPT, would interfere with 
their growth and metastasis in vivo. To test this hypothesis, we used our recently 
developed orthotopic nude mouse model of HSC-3-derived tongue OSCC (93). For 
these studies, HSC-3 cells were transduced with lentiviral dsRED to facilitate tracking 
of the tumorigenic process, cells were injected into the tongues of nude mice (n = 
8/group) and after two days, the tongues of one group of mice were treated topically 
with tunicamycin (25 µg/kg, every third day), while the control group was treated with 
vehicle, 0.9 % NaCl (25 µg/kg, every third day). Results showed that 16 days after 
initiation of tunicamycin treatment, there was a discernable reduction in tumor size in 
response to GPT inhibition, and this trend continued until the animals were sacrificed 
at 25 days post injection (Figure 13). In addition to reducing tumor growth (Figure 13), 
treatment with tunicamycin significantly interfered with metastases as determined by 









Figure 14.  Oral application of tunicamycin inhibits orthotopic tongue tumors induce 
by tongue injection of HSC3 cells. (A) Orthotopic tongue tumors were generated by 
injecting HSC3 cells expressing DsRed into the tongues of nude mice (n=14) and 
imaged by In vivo Live imaging system (IVIS 200) at regular interval starting at day 
17 to day 25. The mice were randomly assignged to tow groups (n = 7/ condition). 
These separate groups were treated with tunicamycin (0.25 mg/kg) or vehicle (0.9 % 









Figure 15.  Oral application of tunicamycin inhibits orthotopic tongue tumors induce 
by tongue injection of HSC3 cells. (B) In vivo imaging of HSC-3- DsRed cells injected 
shows primary tongue tumor growth 21 and 25 days post injection (B) Caliper 
measurements at different internals shows growth of tongue tumors in the group treated 
with tunicamycin compared to control (n=7/ condition; * P<0.01; 2-way  ANOVA); 
(C) Quantification and normalization of fluorescence intensity data for IVIS imaging 
which is represntative of tumor HSC-3 induced primary tongue tumor growth and 









To better understand the effects of GPT inhibition on HSC-3 cell-derived tumor 
behavior, we processed vehicle- and tunicamycin-treated tumors for hematoxylin and 
eosin (H&E) staining and for immunofluorescence analysis. Comparison of H&E 
staining revealed significant differences in tissue morphologies between vehicle- and 
tunicamycin-treated tumors (Figure 14, 15). In untreated tumors, OSCC cells displayed 
striking finger-like projections into the tongue stroma, suggesting cellular invasion and 
EMT. In contrast, the tunicamycin-treated tumors exhibited an encapsulated 
morphology, virtually lacking these invasive cells (Figure 14). To determine if 
inhibition of GPT by treatment with tunicamycin impacted the invasive behavior of 
tumor xenografts, tissue sections were processed for immunofluorescence analyses of 
GPT, E-cadherin, vimentin, IQGAP1 and β-catenin. Results showed that in untreated 
tumors, GPT expression was extensive throughout the tumor tissue, including cells at 
the tumor’s periphery that appeared to be invading into the connective tissue stroma 
(Figure 15, GPT). These cells had a similar staining pattern to vimentin, indicating 
association of GPT with mesenchymal-like aggressive tumor cells (Figure 15, 
vimentin). Interestingly, IQGAP1 also exhibited prominent localization in invasive 
cells in vehicle-treated tumors, suggesting its role in OSCC cell migration in vivo. In 
contrast, tunicamycin-treated tumors displayed virtual loss of invasive cells coincident 
with greatly diminished overall vimentin staining. Since tunicamycin functions as a 
competitive inhibitor of GPT activity without affecting GPT expression per se, it was 
not surprising that GPT abundance was not greatly altered in tunicamycin-treated 
tumors. However, in addition to the loss of vimentin positive cells, tunicamycin-treated 
tumors exhibited reduced IQGAP1 expression that was restricted to encapsulated 





localization of β-catenin with E-cadherin, as well as in an increased junctional 
distribution of E-cadherin and γ−catenin in treated tumors, signifying the presence of 
more mature E-cadherin junctions (Figure 15, β-catenin, E-cadherin, γ−catenin).   
             
Figure 16. Harvested tumors were analyzed by H&E staining for differences in 
histology. Untreated tumors were characterized by streaks of invasive cells growing out 
of the primary tumor into the tongue stroma, tunicamycin-treated tumors exhibited 











Figure 17. Immunofluorescence localization of GPT revealed that it was prominently 
expressed throughout the tumor, including the invasive cells within the tongue stroma.  
GPT staining coincided with vimentin, a marker of EMT and a major driver of cell 
migration. Treatment with tunicamycin abrogated invasive GPT+ vimentin+ cells. 
Untreated tumors displayed both junctional and cytoplasmic β-catenin, as evidenced by 
overlaps with E-cadherin within parts of the tumor body. Some regions of untreated 
tumors had greatly reduced E-cadherin, consistent with EMT.  In tunicamycin treated 
tumors, β-catenin was more junctional, which corresponded with broader junctional 
expression of E-cadherin. Also, untreated tumors displayed increased IQGAP1 
expression in both the cytoplasm and junctions. IQGAP1 has been shown to promote 
cell motility and to function as a junction destabilizer.  While γ-catenin was restricted 
to the central regions of the untreated primary tumor, it was localized to E-cadherin 
junctions in tunicamycin treated tumors, likely to stabilize cell-cell adhesion.   
 
 
DPAGT1 induces oncogenic gene signatures in HSC-3 cells 
 
Given that DPAGT1 can induce mesenchymal properties in MDCK, HOK  and 
indolent CAL27 OSCC cells, as well as in orthotopic oral cancer mouse models in vivo, 





microarray analysis of HSC-3 cells in which DPAGT1 expression was down-regulated 
with shRNA by 93% compared to cells treated with non-targeting shRNA (n=3 per 
experimental group). Principal Component Analysis (PCA) was then performed. PCA 
is a mathematical transformation that collapses the variance between samples across a 
set of large set of variables (here, all ~20,000 genes on the array) into a much smaller 
set of variables called Principal Components (PCs). These "meta-variables" are 
arranged such that PC1 explains the most variance in the data, followed by PC2. PCA 
was performed using all genes across all samples, and a plot was made of PC2 vs. PC1. 
Principal component analysis confirmed that there was a substantial separation between 
the DPAGT1 knockdown and control groups, suggesting that DPAGT1 inhibition had 
a strong effect on genome-wide expression (Figure 16). 
 






Hierarchical clustering further showed that triplicate samples with DPAGT1 
knockdown clustered together compared to the control triplicates. Differential analyses 
of knockdown versus control identified 70 genes with upregulated expression 
(DPAGT1-repressed) and 211 genes with down-regulated expression (DPAGT1-
activated) with FDR-corrected q-value ≤ 0.05 and fold change ≥ 1.5. 
Significantly, interrogation of the microarray data for changes in the expression 
of EMT genes identified by us as targets of DPAGT1 in CAL27 and HSC-3 cells, 
revealed association with the ZEB family of transcription factors. Likewise, there was 
a significant, 2-fold, change in the expression of N-cadherin, while no major changes 
in the transcriptional expression of vimentin and fibronectin were detected. 
We next examined the expression of genes with roles in EMT, including 
CTHRC1, in TCGA and found that they were differentially expressed between tumor 
specimens and normal adjacent epithelia, although their association with grade and 
stage varied. To further validate the role of DPAGT1 in EMT in human OSCC, we used 
the DPAGT1-activated genes signature to define a ‘DPAGT1 activity score’ based on 
Adaptive Signature Selection and InteGratioN (ASSIGN) to capture coordinated co-
expression of DPAGT1 targets reflecting the corresponding regulators’ activities. 
Using the DPAGT1 ‘activity score’, we tested for association between DPAGT1 and 
ZEB1 and SNAI2 in TCGA and found highly significant association. In addition, to 
assure that the differential expression was not driven by the “tumor versus normal” 
distinction only, we repeated the analysis within the tumors only. Shown in (Figure 17) 
are box plots documenting a direct relationship between DPAGT1 activity and ZEB1, 






Figure 19. (A). Stratification of human OSCC samples using DPAGT1 knockdown 
(shRNA KD) gene signature from HSC-3 cells revealed strong enrichment of genes 
expressed in OSCC, with the large majority of DPAGT1-induced genes (ie. genes 
repressed upon DAPGT1 knockdown) enriched in tumors. (B). The set of DPAGT1 
upregulated genes was projected onto the TCGA OSCC RNASeq dataset (n=352) using 
ASSIGN. DPAGT1 activity score was associated with ZEB1 expression, as well as 
with additional markers of EMT, SNAI2, TWIST1,2, and YAP. In addition. DPAGT1 
activity was associated with CTHRC1, a prometastatic glycoprotein that we showed 
was regulated by N-glycosylation (Liu et al., JBC, 2013).   
These results provide support for the role of DPAGT1 in promoting oncogenic 





Section 1: N-glycosylation in HNSCC Highlights 
 
• Aberrant activation of the DPAGT1 gene was associated with HNSCC 
aggressive traits by driving hyper-glycosylation of E-cadherin concomitant with 
the loss of intercellular adhesion and induction of the Wnt/β−catenin-N-
glycosylation positive feedback loop.  
• Ectopic expression of DPAGT1 in indolent CAL27 cells induced EMT by 
upregulating a key transcription factor, ZEB1, along with mesenchymal 
proteins, vimentin and fibronectin, and by inhibiting GSK3β activity led to an 
increased abundance of active β-catenin. 
• Partial knockdown of DPAGT1 in aggressive HNSCC HSC-3 cells reduced 
expression of EMT markers and cell migration while enhancing intercellular 
adhesion. 
• Inhibition of the GPT enzyme with tunicamycin interfered with orthotopic 
tongue tumor growth and metastasis in nude mice coincident with diminished 
expression of vimentin-positive cells invading the tongue stroma.  
• Analyses of global gene expression changes associated with DPAGT1 
knockdown in HSC-3 cells defined DPAGT1-activated gene signatures as 
enriched in pro-tumorigenic transcription factors and signaling pathways, 
including EGFR and Akt. 
• DPAGT1-activated genes were coordinately upregulated with tumor grade in 
human HNSCC in TCGA highlighting DPAGT1 expression as a predictor of 





Section 2: Wnt/β-catenin in HNSCC 
 
MATERIALS AND METHODS 
Cell Lines and EC50 Measurements 
Cell lines were obtained from the following sources: human CAL27, SCC9, and 
SCC25 cells were purchased from ATCC, and human HSC-3 cells were obtained from 
XenoTech, Japan. All cell lines were authenticated by short tandem repeat DNA 
profiling every 6 months either by ATCC or Genetica, with last validation in October, 
2016. Cells were grown at 37oC under 5% CO2 to 70% confluence in DMEM 
(Invitrogen) supplemented with 10% fetal bovine serum, penicillin, and streptomycin, 
as described (48). Determination of EC50 in response to ICG-001 treatment at different 
concentrations of the drug was carried out using IncuCyte live-cell imaging per 
manufacturer’s instructions (Essen BioScience). Briefly, OSCC cells were grown in 
T75 flasks, collected by trypsin digestion and washed in 5-10 ml DMEM media 
containing 10% FCS. Cells were seeded in Essen Bioscience 96 well Image Lock plate 
(Bioscience 96 well ImageLock Microplate #4379) at a density of 2000-3000 cells/well 
and allowed to attach for 12-24 hours. Next, cells were treated with different 
concentrations of ICG-001 (Selleckchem):0.1, 0.3, 1, 3, 10, 20 and 30 µM and 
examined at 6-hour time intervals. After 72 hours, data were transferred to the Excel 






Nude Mice and Orthotopic Xenograft Experiments  
All experiments were approved by the Boston University Medical Center 
Institutional Animal Care and Use Committee.  HSC-3 cells were lentivirally 
transduced with DsRed and suspended in serum-free Dulbecco’s modified eagle 
medium (DMEM). For orthotopic tongue xenografts, 0.5 × 106 cells in 40 µl of DMEM 
were injected into each tongue of two-month old nude mice (Taconic Farms, Hudson, 
NY) that were anesthetized with isoflurane. Anesthesia was administered in an 
induction chamber with 2.5% isoflurane in 100% oxygen at a flow rate of 1 L/min and 
then maintained with a 1.5% mixture at 0.5 L/min. Two days following injection, mice 
(n=16) were equally divided into two groups: vehicle (DMSO control) and ICG-001-
treated. For tumor inhibition studies, ICG-001 was diluted in 0.1% DMSO and 
administered via oral gavage at a concentration of 80 mg/kg into treatment-group mice 
via the tongue. Digital caliper measurements were performed at 2 – 3 day intervals to 
monitor the volumes of all tumors. Mice were imaged for DsRed protein expression on 
day 17 using an IVIS 200 system (Xenogen, Alameda, CA, USA). The fluorescence 
signals were optimized for the DsRed protein at excitation 570 and emission 620. 
Fluorescence region of interest (ROI) data were calibrated and normalized fluorescence 
efficiency (p/s/cm2/sr)/(µW/cm2) determined as per the instructions (Perkin Elmer, 
USA). The data are reported as normalized fluorescence intensity (FU) from a defined 
region of interest for oral tongue tumors or systemic metastases compared to control 
vehicle-injected mice. Mice were sacrificed at day 20 and tumors were harvested and 






Immunocompetent SCC Mouse Model  
HPV-16 E6 and E7-expressing TC-1 tumor cells were used which were 
generated as previously described (94). In brief, the HPV-16 E6, E7, and ras oncogene 
were used to transform primary C57BL/6 mice lung epithelial cells to generate the TC-
1 tumor cell line. TC-1 has been reliably used as a preclinical model to study HPV16 
E7-specific CD8+ T-cell responses for the evaluation of novel immunotherapeutic 
agents to support Phase I clinical trials in human subjects (95). The cells were 
maintained in RPMI medium supplemented with 2 mM glutamine, 1 mM sodium 
pyruvate, 100 U/ml penicillin, 100 µg/ml streptomycin, and 10 % fetal bovine serum. 
C57BL/6 mice were inoculated subcutaneously in the right flank with 1 × 105 TC-1 
cells per mouse. When the tumor volume reached 50 mm3 (7 days post-inoculation) 
mice were treated daily with either 50 µl of ICG-001 (0.04 mg/µl; 80 mg/kg BW) or a 
mixture of 10% DMSO+90% vegetable oil (Vehicle control group) administered orally 
using a 16-gauge oral feeding tube daily for seven days. Mice were sacrificed, and 
tumors were dissected and processed as described below.  
 
Mouse Tumor Sample Processing  
Tumors were harvested at sacrifice at day 20, weighed and either snap-frozen 
and processed for histology, immunohistochemistry, immunoblot and flow cytometry 
analyses. Tumors were paraffin-embedded and 5 µm sections were placed on 
Fisherbrand Superfrost Plus Microscope Slides (Fisher Scientific), deparaffinized, 
treated with Retrievit-6 Target Retrieval Solution (BioGenex), and processed for 
immunofluorescence and histological analyses (see below). Frozen tumor tissues were 





digested with 0.1% collagenase I (Worthington) at 37°C for 1 hour. Cells were passed 
through 70 µm mesh, washed twice and the resulting single-cell suspension was used 
for flow cytometric analysis and sorting.  
 
Immunofluorescence Analysis 
Morphologies of OSCC cell lines comprising non-metastatic (CAL27) and 
metastatic (HSC-3, SCC9 and SCC25) cells treated with ICG-001 or DMSO vehicle 
control were examined using a Nikon Eclipse TE300 microscope. For indirect 
immunofluorescence analyses, cells were grown to 70% confluence on Nunc Lab-Tek 
II Chamber Slide (Thermo Fisher Scientific), fixed in 3.7% paraformaldehyde, 
permeabilized with 0.1% Triton X-100, blocked with 10% goat serum, and incubated 
with primary antibodies to β-catenin (Abcam, rabbit polyclonal AB followed by 
secondary antibody, goat anti-rabbit conjugated with Alexa Fluor 488 (Jackson 
ImmunoResearch). Sections were counterstained for nuclei with 4'6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Molecular Probes), mounted in ProLong Gold 
Antifade, (Molecular Probes) and images were analyzed with a Zeiss LSM 710-Live 
Duo Scan confocal microscope. 
Mouse tumor tissue sections were blocked with 10% goat serum, mouse IgG 
blocking reagent (Vector) and incubated with antibodies against β-catenin, E-cadherin 
(Abcam, rabbit) and vimentin (Sigma, mouse) followed by secondary antibodies, goat 
anti-rabbit and goat anti-mouse conjugated with Alexa Fluor 488. Negative controls 
lacked primary antibodies. The slides were mounted in ProLong Gold Antifade and 
optical sections (0.5 µm intervals) were analyzed by confocal microscopy using a Zeiss 





between samples, settings were fixed to the most highly-stained sample with all other 
images acquired at those settings. Images were processed with ZEN 2 and ImageJ 
imaging software. 
 
Immunoblot Analysis  
Total cell lysates (TCL) from DMSO or ICG-001-treated HSC-3 cells were 
prepared by extraction with Triton/β-octylglucoside buffer, as described (15).  Total 
tissue lysate (TTL) from harvested mouse orthotopic tongue tumors was prepared by 
grinding tumors to a fine powder in liquid nitrogen, and extracting total tissue proteins 
with Triton/β-octylglucoside buffer. Protein concentrations for TCL and TTL were 
determined using BCA assay (Pierce). For immunoblot analyses, TCL and TTL (20-30 
µg of total protein) were fractionated on 7.5% SDS-PAGE, transferred onto 
polyvinylidene difluoride membranes, blocked with 5% nonfat dry milk, and incubated 
with primary antibodies to E-cadherin and β-catenin (TCL; BD, mouse) (TTL; Abcam, 
rabbit) and GAPDH (Novus Biologicals)). Protein-specific detection was carried out 
with horseradish peroxidase-labeled secondary antibodies conjugated to horseradish 
peroxidase (Bio Rad), and Enhanced Chemiluminescence Plus (Amersham 




Mouse tumor tissues were fixed overnight in 4% paraformaldehyde in PBS and 
dehydrated. Samples were embedded in paraffin and sectioned (5-µm thickness) and 





Pathology Core Facility. Digital images of stained slides were acquired with a TE 300 
microscope (Nikon). 
 
Zebrafish Transplantation and ICG-001 Treatment 
Zebrafish husbandry was performed as described (96) in zebrafish facility at the 
Boston University School of Medicine, in accordance with IACUC-approved protocols. 
Casper x Fli-GFP fish breeders were crossed and embryos overexpressing GFP in their 
vasculature were obtained. For micro-injections of zebrafish embryos, OSCC cells 
were either stained with a CellTrackerTM dye (Molecular Probes) or lentivirally 
transduced with red fluorescent protein (RFP), trypsinized and resuspended at a 
concentration of 50x106 cells/ml in DMEM containing 10% FBS. One day post-
fertilization, (dpf) embryos were enzymatically dechorionated using Pronase (Roche 
Diagnostics) and allowed to recover overnight at 28ºC, in the dark and in sterilized egg 
water. The two-dpf zebrafish larvae were anesthetized with Tricaine and immobilized 
before injections. The borosilicate glass capillaries (World Precision Instruments) 1.0 
mm O.D. x 0,78 mm (I.D. Harvard Apparatus) used for micro-injection were pulled 
using 500 Volts (pull=100, velocity=250) in a capillary machine (Sutter Instrument). 
The OSCC cell transplantations were performed by injection of ~1nL directly into the 
perivitelline space (97) of the embryo using a needle holder and a micro-injection 
station (World Precision Instruments). The transplanted zebrafish embryos were treated 
with ICG-001 or vehicle and incubated in the dark at 34.6ºC. Zebrafish embryos were 
individually mounted in a low melting 1.5% agarose gel (Fisher bioreagents) for a side 
view and imaged using an Olympus MVX10 fluorescence stereomacroscope or a Leica 





Zebrafish statistical analysis was carried out using GraphPad PRISM software. 
CAL27 and HSC-3 injected zebrafish were monitored and counted for a comparison of 
metastasis. Fish showing OSCC cells spread outside of the injection site (tumor burden) 
were counted manually in each group and compared with a t-test (HSC3 vehicle (n=86) 
vs CAL27 vehicle (n=68) P-value <0.0001, t-test (HSC-3 vehicle (n=86) vs HSC-3 
ICG-001 (n=104) P-value <0.0001. 
To determine if HSC3 zebrafish xenograft model could serve in the analyses of 
subpopulations of aggressive OSCC cells, we tagged these cells with a Red Fluorescent 
Protein (RFP).  The transplanted zebrafish larvae were monitored over time (2 hours 
and 24 hours post injection) and imaged individually and as groups. Metastatic cells 
were counted manually per fish and reported for statistical analysis using student’s t-
test. The samples were: 2 hours post injection t-test (HSC3 unsorted vehicle (n=3) vs 
HSC3 sorted high vehicle (n=3) P-value <0.002, T-Test (HSC3 sorted low vehicle 
(n=3) vs HSC3 sorted high vehicle (n=3) P-value <0.002. 24 hours post injection t-test 
(HSC3 unsorted vehicle (n=6) vs HSC3 unsorted ICG-001 (n=6) P-value <0.0001, t-
test (HSC3 sorted low vehicle (n=6) vs HSC3 sorted low ICG-001 (n=6) not significant. 
t-test (HSC3 sorted high vehicle (n=5) vs HSC3 sorted high ICG-001 (n=11) P-value 
<0.0001. 
 
Flow Cytometry and Fluorescence-activated Cell Sorting (FACS) 
For characterization of cells from immunocompetent SCC mouse model  by 
multicolor flow cytometry staining, cells were first incubated with Zombie Aqua Live-
dead dye (Biolegend) in PBS for 20 min, washed, pre-blocked with mouse antiCD16/32 





mouse antibodies: CD29 eFluor 450, CD166 PE and CD133 PerCP-e710 
(eBioscience), CD44 BV786, EpCAM FITC, E-Cadherin PE-Cy7, CD24 Alexa Fluor 
647 and CD45 APC-750 (Biolegend) for 30 min. Cells were washed and immediately 
run on the BD FACSARIA II flow cytometry sorter for sorting and analysis. At least 
200,000 events were recorded per sample. Data were analyzed in FACSDiva v6.2.0 
(BD) and FlowJo v10.2 (FlowJo). 
For zebrafish studies, cells were prepared for flow cytometry as a single-cell 
suspension and stained with Zombie Aqua Live-Dead dye (Biolegend) in DPBS for 20 
min in the dark according to manufacturer’s protocol, then washed and pelleted by 
centrifugation. The cell pellet was resuspended in DPBS/BSA/EDTA buffer containing 
Brilliant Buffer (BD Biosciences) and fluorochrome-conjugated antibodies to human 
CD29 (Alexa Fluor 700, Biolegend), human CD24 (BUV395, BD Biosciences), human 
EpCAM (BV650, BD Biosciences) and human CD44 (BV421, Biolegend), incubated 
for 30 min in the dark, then washed and pelleted twice. The resulting cell pellet was 
resuspended in DPBS/BSA/EDTA buffer and immediately analyzed on a BD 
FACSAria II SORP sorter located in the Flow Cytometry Core Facility at Boston 
University Medical Center (BUMC) using the BD FACSDiva 6.2 software. For 
analysis, at least 100,000 events per sample were recorded and data were subsequently 
analyzed with FlowJo 10.2 software (FlowJo, Inc). For quality controls, purity of the 
sorts was confirmed to be >95%.  
 
Microarray Gene Expression Analysis  
Three separate wells (triplicate) from 6 well plates were seeded by HSC-3 and 





confluency), the cells were treated with either 0.1% DMSO or 10 µM ICG-001. After 
48-64 hours, the cells were trypsinized and harvested for RNA purification using 
miRNeasy Micro Kit (QIAGEN #217084). Gene expression profiling was performed 
in triplicates per treatment group (n=3) using Human Gene 2.0ST arrays. Raw 
expression values were normalized together using the Robust Multiarray Average 
(RMA) with the affy R package. A BrainArray Chip Definition File (CDF) was used to 
map the probes on the array to unique Entrez Gene identifiers 
(http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF). 
 Differential gene expression analysis with respect to ICG-001 treatment was 
performed for each cell line using the Limma R package v3.14.4 (98). Filtered false 
discovery rate (FDR) q-values were recomputed based on the Benjamini-Hochberg 
method (91) after removing genes that were not expressed above the array-wise median 
value of at least one array. Only genes with absolute linear fold-change > 1.5 and 
filtered FDR q < 0.01 were considered and used for further analysis as the ICG-001 
treatment signature.  
 
TCGA OSCC Data Processing and Analysis 
RNA-sequencing (RNASeq) expression and matched clinical data pertaining to 
TCGA OSCC samples (n=352) was obtained and processed as previously described 
(99). The set of HSC-3 ICG-001-down-regulated genes (N=1,238) was projected onto 
TCGA RNASeq data using ASSIGN (100), yielding sample stratification based on the 
coordinated level of ICG-001-down-regulated gene expression (measured by ICG-001-
inhibition ASSIGN scores). Only samples with known tumor grade information were 





performed using the survival package in R (https://cran.r-project.org/). Patient survival 
information pertaining to the February 4th 2015 Firehose release was used to compute 
overall survival for TCGA OSCC patients. Patients were divided into two groups (ICG-
001-high and -low) based on the median ASSIGN scores pertaining to ICG-001 
inhibition. AE and metastatic tumor samples were filtered out for this analysis (i.e. only 
the primary tumor-associated ASSIGN scores were used to bin samples into ICG-001 
high, and low groups).  
 
Statistical Analyses 
Statistics for comparing relative abundances of TCL and TTL obtained using 
immunoblot assays, orthotopic mouse tumor volume, and relative radiant efficiency 
measurements between ICG-001 and DMSO vehicle-treated (control) groups were 
obtained using an unpaired two-tailed t-test. Mouse tumor volume measurements were 
compared between groups per time point. ICG-001 ASSIGN scores for OSCC versus 
AE TCGA samples were compared using an unpaired two-tailed t-test. Analysis of 
scores with respect to tumor grade was done using a pairwise one-sided t-test between 
adjacent grade groups (g2 vs g1, g3 vs g2 and g4 vs g3), with their corresponding p-
values combined as previously described (101). A log-rank test was used to compare 
survival rates between the ICG-001-high and -low patient groups. 
 
Data Availability 
Microarray gene expression profiling data pertaining to ICG-001 and DMSO 
(vehicle) control treatment in HSC-3 and CAL27 cells, and CTNNB1 knockdown in 





database, with a pending GEO series ID. The data will be immediately made publicly 
























Inhibition of β-catenin transcriptional activity interferes with OSCC cell growth and 
drives junctional localization of β-catenin in vitro 
Given that intrinsic nuclear activity of β-catenin has been associated with 
treatment-resistant features of carcinomas (102), we examined whether interference 
with transcriptional activity of β-catenin/CBP with a small molecule inhibitor, ICG-
001 (Figure 18), would impact proliferation and cellular phenotypes of OSCC cells. 
First, we assessed the in vitro sensitivity to ICG-001 of a panel of OSCC cell lines 
comprising non-metastatic (CAL27) and metastatic (HSC-3, SCC9 and SCC25) cells 
using incuCyte live imaging. Dose-dependent inhibition of cell growth was observed 
for all cell lines examined following 72 hours of treatment with ICG-001, with EC50 
values of 2.3 µM, 2.8 µM, 5.4 µM and 8.3 µM for HSC-3, SCC25, SCC9, and CAL27 
cells, respectively (Fig. 19).  
 
 









Figure 21. Determination of half maximal effective concentration (EC50) for ICG-001 
effects in OSCC cell lines. Shown are graded dose response curves for ICG-001 in 
HSC-3, CAL27, SCC9 and SCC25 cell lines for 72 hours of treatment. 
 
Notably, the metastatic cell line HSC-3 was more sensitive to ICG-001 
compared to the indolent CAL27 cells (Figure 19). For the subsequent studies, we 
focused on CAL27 and HSC-3 cells to represent non-metastatic and metastatic 
phenotypes, respectively. Given that E-cadherin expression and localization indicates 
the status of intercellular adhesion in epithelial cells, we assessed the effects of ICG-
001 on E-cadherin and β-catenin abundance, and on β-catenin localization. While 





or HSC-3 cells (P=0.42, two-tailed t-test), it resulted in a 2-fold increase in E-cadherin 
abundance (P=0.044, two-tailed t-test; Figure 20).  
 
Figure 22. Immunoblot of total cell lysates extracted from HSC-3 cells and analyzed 
with antibodies against E-cadherin and β−catenin, with GAPDH as a loading control. 
Three independent experiments were carried out and a representative immunoblot is 
shown with bar graphs displaying relative protein abundance. Statistical analyses of 
significance comparing relative abundance in ICG-001 to DMSO vehicle-treated 
control cells were obtained using an unpaired t-test; *P < 0.05. 
 
 
To align growth inhibition with β-catenin-dependent cellular phenotypes, we 
next examined localization of β-catenin in OSCC cell lines before and after ICG-001 
treatment using immunofluorescence staining and high-resolution confocal 
microscopy. Remarkably, ICG-001 treatment promoted more focused localization of 
β-catenin to the cell membrane in all four cell lines evaluated suggesting increased 






Figure 23. Immunofluorescence imaging of β-catenin localization in OSCC cell lines 
in response to ICG-001 treatment showing more focused membrane localization of β-
catenin, increased intercellular adhesion with a more pronounced epithelial phenotype. 
Size bars, 10 µm. 
 
ICG-001 impacts expression of genes involved in Wnt signaling, cell proliferation, 
survival and intercellular adhesion  
To determine the effects of disrupting β-catenin-CBP mediated transcription 
with ICG-001 in OSCC cell lines, we performed gene expression profiling of RNA 





control using microarrays. To assess the significance of ICG-001 inhibition on gene 
expression, principal component analysis (PCA) was performed across all probe sets 
and all samples. A plot of PC2 vs. PC1 confirmed that there was a substantial separation 
between ICG-001 and control groups, suggesting that treatment with ICG-001 had a 
strong effect on genome-wide expression (Figure 22). 
 
Figure 24. PCA revealed that samples separated strongly by cell line along the PC1 
axis, accounting for 35% of the total variance in the experiment, indicating that there 
are substantial differences in gene expression changes between the CAL27 and HSC-3 
cell lines. The ICG-001 treated cells separated well from DMSO control treated cells 
along the PC2 axis (explaining 18% of total variance). In addition, separation along the 
PC2 axis by drug versus control was stronger in HSC-3 cells than CAL27, signifying 
larger gene expression changes between drug and control groups in HSC-3 cells. 
 
 Differential gene expression testing was then performed between ICG-001 
treatment and control groups yielded cell type-specific ICG-001 treatment signatures 






Figure 25. Heatmap of microarray gene expression treatment signatures derived from 
metastatic HSC-3 and non-metastatic CAL27 cells. RNA was extracted and profiled 
using microarrays from each cell line and gene expression profiles were compared by 
differential expression testing (ICG-001 treatment versus DMSO vehicle; n=3 per 
treatment group, per cell line). Signatures were derived for each cell line by retaining 
genes with filtered-FDR q < 0.01 and absolute linear fold-change ≥1.5. Row z-scores 
of log-2 expression values per gene are shown. 
 
Consistent with EC50 values in vitro, which demonstrated greater ICG-001 
treatment sensitivity of HSC-3 cells as compared to CAL27 cells, HSC-3 cells showed 





regulated genes) than CAL27 cells (246 up-regulated and 256 down-regulated genes) 
(Figure. 24). 
 
Figure 26. Metastatic HSC-3 cells display higher sensitivity to transcriptional 
dysregulation by ICG-001 treatment than less aggressive CAL27 cells. Venn diagram 
summarizing the size and overlap of treatment signatures in HSC-3 and CAL27 cells is 
shown. 
 
Importantly, genes known to be targets of Wnt/β-catenin signaling (DKK1, 
WNT5B, CCND2, CDK1, LEF1, and SKP2) and to play a role in cell proliferation and 
survival (BIRC5, CCNE1, CCNE2, CCNB1, CCNB2, CDKN3 and CDCA7) were 
significantly down-regulated, while genes with key roles in the formation and 
maintenance of intercellular junctions (CLDN1, CLDN4, CLDN9, CLDN16, CDH4 and 
ICAM1) were up-regulated, with greater effect in HSC-3 cells than in CAL27 cells 






Figure 27. ICG-001 impacts the expression of genes with roles in Wnt/β-catenin 
signaling (blue), cell proliferation and survival (red), intercellular adhesion (green), and 
stem cell-like behavior (purple). (A). Waterfall plot displaying log-2 fold-changes of 
gene expression for all genes included in either HSC-3 or CAL27 treatment signatures 
(n=2,847 genes) is shown with greater effect in aggressive HSC-3 cells compared to 




Of significance, cell markers that were previously identified to be associated 
with a more stem cell-like state in HNSCCs (DNAJC6, NR5A2 and HELLS), 
characterized by elevated β-catenin activity (74), were also found to be significantly 





  To assess whether ICG-001 treatment correlated with β-catenin knockdown in 
OSCC in vitro, we tested by Gene Set Enrichment Analysis (GSEA) the derived ICG-
001 treatment signatures against a gene list ranked by the differential expression of β-
catenin shRNA knockdown versus control in HSC-3 cells. Interestingly, we observed 
a significant positive correlation between ICG-001 treatment and β-catenin knockdown 
(FDR q < 0.001, Figure 26, A), confirming that ICG-001 treatment indeed targets 
specific downstream β-catenin-mediated transcriptional activity in aggressive OSCC 
cells. In addtion, GSEA revelaed that a major oncogenic pathway inhibited by ICG-001 
was nuclear YAP/TAZ (Figure 26, B). Previous studies have shown that YAP/TAZ 
contribute to the etiology and pathogenesis of OSCC (103). Specifically, we have 
shown that YAP/TAZ regulated genes are significantly overexpressed in OSCC TCGA. 






Figure 28. GSEA of in vitro treatment signatures indicates ICG-001 treatment targets 
β-catenin- and YAP/TAZ-mediated transcriptional activity in OSCC. A. shRNA-
mediated knockdown (KD) of β-catenin was performed in HSC-3 cells, followed by 
gene expression profiling using microarrays. Additionally, previously generated 
transcriptional profiling data for YAP/TAZ KD in HSC-3 cells was used (2). A ranked 
reference list of genes was generated in decreasing order of t-statistic for differential 
expression, obtained by comparing the KD (n=3) versus scrambled shRNA control 
(n=3) groups (n=23,744 and 23,466 genes for β-catenin and YAP/TAZ KD 
experiments, respectively). The ICG-001 treatment signature (both up- and down-
regulated genes) were queried for enrichment with respect to each of the KD ranked 
reference gene lists. Mountain plots for GSEA with respect to β-catenin B. YAP/TAZ 
KD indicate ICG-001-up- and down-regulated genes are significantly skewed towards 
up- and down-regulation upon β-catenin or YAP/TAZ KD, respectively. Reported FDR 








ICG-001 inhibits OSCC tumor growth and aggressive phenotypes in vivo 
Our previous studies have shown that HSC-3 cells drive orthotopic tumor 
growth and metastasis in nude mice in vivo (88). To determine whether ICG-001 
treatment impacted growth and metastasis of HSC-3 xenografts, we treated mice with 
either ICG-001 (n=8) or DMSO vehicle (n=8) by oral gavage beginning on day three 
following cell implantation into the tongues of nude mice, with treatment repeated 
every day. For these studies, cells were transduced with red fluorescent protein (DsRed) 
to track tumor growth and metastasis prior to orthotopic inoculation. Primary tumor 
growth was monitored every two to three days using caliper measurements. In addition, 
in vivo imaging system (IVIS) was used to locate DsRed-expressing cells. Starting at 
13 days post-inoculation, we observed a significant reduction in tumor volume (P < 
0.005, two-tailed t-test) following treatment with ICG-001, relative to vehicle treated-
control mice (Figure 27).  
 
 
Figure 29. Caliper measurements confirmed significantly reduced primary tumor 
volume in ICG-001- compared to DMSO-treated mice starting at day 13 with continued 






Further, comparison of relative radiance efficiencies at day 17 post-inoculation 
revealed significantly-reduced primary tumor growth (P = 4.65e-3, two-tailed t-test) 
and whole body metastases (P = 0.013, two-tailed t-test) associated radiance intensities 
in the treated versus control groups (Figure 28).  
 
Figure 30. HSC-3 cells (0.5 × 106 cells/40 µl DMEM) were lentivirally transduced with 
DsRed and injected into tongues of two-month old nude mice. Tumor formation and 
metastasis were visualized using IVIS fluorescent imaging at day 17; representative 
images for mice treated with ICG-001 (n=8; bottom) or DMSO vehicle (n=8; top), and 
for control mice (n=2) are shown. Total radiant efficiency of cells in the primary tongue 
tumor and of cells that metastasized to other organs was significantly reduced upon 
ICG-001 treatment for both the primary tongue tumor and whole body metastases 
(shown as the mean (+S.D.) (Unpaired t-test; * P < 0.05; ** P < 0.005). 
 
Histological hematoxylin and eosin (H&E) analysis of vehicle-treated tumors 
revealed streaks of invasive cells growing out from primary tumors into the tongue 








Figure 31. Harvested tumors were analyzed by H&E staining for differences in 
histologies. ICG-001-treated tumors exhibited a capsular phenotype, in contrast to 
vehicle-treated tumors that showed streaks of invasive cells growing into the tongue 



































Interestingly, examination of E-cadherin protein levels by immunoblot revealed 
that ICG-001 treated tumors had increased E-cadherin abundance compared to vehicle 
control-treated tumors (P = 0.016, two-tailed t-test), while levels of β-catenin were not 
significantly altered (P = 0.67, two-tailed t-test; Figure 30).  
 
Figure 32. Total tissue lysates were prepared from mouse tumors (n=4 per treatment 
group) and analyzed by immunoblot for E-cadherin and β-catenin protein levels after 
normalization to GAPDH. Immunoblot and bar graphs displaying relative protein levels 
are shown (Unpaired t-test; * P < 0.05; ** P < 0.005). 
 
 
Immunofluorescence analyses of these tumors showed that the ICG-001-treated 
tumors phenocopied ICG-001-treated OSCC cell lines in vitro and displayed robust E-
cadherin and β-catenin junctional localization with an almost complete loss of a 
mesenchymal protein vimentin, further indicating that ICG-001 promoted an epithelial 






Figure 33. Immunofluorescence imaging of E-cadherin, β-catenin and vimentin in 
HSC-3 derived OSCC tumor xenografts from mice treated with either DMSO vehicle 
(top) or ICG-001 (bottom). ICG-001 enhanced the recruitment of E-cadherin and β-
catenin to cell-cell contacts, while reducing the expression of vimentin.  
 
Given that our in vivo model was based on an immunocompromised mouse, it 
was possible that the observed tumor-inhibitory effects of ICG-001 were enhanced by 
the absence of the immune system. We therefore further tested whether ICG-001 
inhibited aggressive phenotypes and promoted membrane localization of β-catenin in 
an immunocompetent mouse model of squamous cell carcinoma (SCC) (104). 
Specifically, we assessed the effects of ICG-001 treatment on TC-1 tumor xenografts 
from syngeneic C57BL/6 mice. Strikingly, we found that treatment with ICG-001 
completely abrogated aggressive mesenchymal-like phenotypes of dissociated tumor 
cells coincident with the acquisition of a cuboidal epithelial-like morphology with 






Figure 34. Immunofluorescence imaging of β-catenin in HPV-16 E6 and E7-expressing 
TC-1 tumor cells.  ICG-001 induces a cuboidal phenotype in cells dissociated from TC-
1 tumors and promotes expression of junctional β-catenin. Representative images are 
shown for ICG-001 treatment versus DMSO (vehicle) control conditions. 
 
To determine if changes in β-catenin localization were also associated with 
different GPT distribution, we carried out Immunofluorescence analysis for GPT in 
dissociated tumor cells (Figure 33).  Results showed that cells from vehicle treated 
tumors displayed a broad pattern of GPT immunostatining that accompanied their 
mesenchymal phenotype. In contrast, cells from tumors treated with ICG-001 exhibited 
an epithelial morphology with perinuclear localization of GPT.  
 
Figure 35. Immunofluorescence imaging of GPT in HPV-16 E6 and E7-expressing TC-







Phenotyping these tumor cells for cell surface markers of cancer stem-like cells 
(CSCs) CD44, CD24 CD29, CD133, CD166 identified a subpopulation of CD29+- and 
E-cadherin-expressing (CD29+E-cad+) cells enriched for CD24 and CD133 
(CD24highCD133+E-cad+; Figure 34). Treatment with ICG-001 dramatically reduced 
the abundance of this stem-like cell population (Figure 34).  
 
 
Figure 36. Flow cytometry phenotyping of TC-1 tumor cells. Live, single cells were 
further gated based on expression of CD45, CD24, CD29, CD133 and E-cadherin (E-
cad) as shown (red arrows), and expression profiles of stem-cell-like 
CD24highCD133+E-cad+ (red histograms, black arrows) were compared to CD24-
CD133-E-cad- (blue histograms). Stem-cell-like CD24highCD133+E-cad+ population in 








Further, immunofluorescence staining for β-catenin of FACS-sorted 
CD29+CD24highCD133+E-cad+ cells from those tumors confirmed that ICG-001 
treatment promoted membrane localization of β-catenin (Figure 35). These results 
showed that ICG-001 inhibited aggressive phenotypes of TC-1 cells in a manner similar 
to OSCC and that its effects were not significantly impacted by an immune competent 




Figure 37. Localization of β-catenin in FACS-sorted CD24highCD133+E-cad+ cells. 
Treatment of CD24highCD133+E-cad+ cells with ICG-001 resulted in increased 
membrane distribution of β-catenin compared to vehicle-treated cells.  
 
 
ICG-001 selectively targets a stem cell-like tumor subpopulation in vivo 
The nuclear activity of β-catenin has been shown to promote immature stem-
like cell phenotypes (74, 105). In particular, a subset of nuclear β-catenin-positive cells 
from HNSCC, expressing the marker CD44 found on tumor stem cells, were also shown 
to co-express CD24 and CD29 to promote non-adherent tumor sphere growth and to 





001 target stem like cells. Thus, to assess if ICG-001 inhibited the ability of 
CD44+CD24highCD29+ cells to drive rapid OSCC tumor growth and metastases, we 
applied an embryonic zebrafish xenograft model as a tool to screen for aggressive stem 
cell-like subpopulation of OSCC cells. Due to its small size, transparency, and close 
homology with its human counterpart, the zebrafish xenograft model possesses unique 
advantages enabling the rapid screens of aggressive human OSCC stem-like cells (106).  
 Embryonic zebrafish lack an adaptive immune system and are excellent for 
screening human CSC. We first examined the behavior of CAL27 and HSC-3 cells in 
two-day post-fertilization (2-dpf) zebrafish, which lack an adaptive immune system. 
CAL27 and HSC-3 cells were labeled with a fluorescent tracker dye and 100-200 cells 
were injected into zebrafish embryos as described (see Materials and Methods). The 
behavior of cell tracker dye-stained OSCC cells in zebrafish closely mimicked our 
orthotopic mouse models in their ability to grow tumors without and with metastatic 
properties, respectively (Figure 36 & 37). Additionally, treatment with ICG-001 
reduced tumor size and metastasis in zebrafish tumors induced by CAL27 and HSC-3 







Figure 38.  HSC-3 and CAL27 cells were transduced with a CellTrackerTM and 100 – 
200 cells in ~1nL were injected directly into the periviteline space of the embryo 
(n=50/cell line). After 24 hours, CAL27 cells formed tumors that did not metastasize, 

























Figure 39. Immunofluorescence imaging of CellTrackerTM-labeled CAL27 and HSC-3 
cells revealed that treatment with ICG-001 inhibited CAL27 cell-driven tumor growth, 
as well as growth and metastasis of HSC-3-derived tumors. N=68 CAL27 vehicle, n=84 
CAL27 ICG-001, n=86 HSC-3 vehicle, n=104 HSC-3 ICG-001, unpaired t-test; 
****p<0.0001.   
 
Since it has been shown that a specific subpopulation of aggressive tumor cells 
are associated with stem-like properties, we assessed CD24, CD29 and CD44 
expression in HSC-3 cells by flow cytometry (74). HSC-3 cells, transduced with 
lentiviral red fluorescent protein (RFP), displayed high levels of CD44 and CD29 
expression but varying levels of CD24 expression. To determine the role of β-catenin 
on aggressive behavior of OSCC cell subpopulations, we used fluorescence activated 
cell sorting (FACS) to isolate CD44+CD24lowCD29+ and CD44+CD24highCD29+ cells 






Figure 40. Identification of subpopulations of RFP-transduced HSC-3 cells with 
primitive antigenic cell markers CD44+CD24highCD29+ by flow cytometry. 
 
After sorting, CD44+CD24lowCD29+, CD44+CD24highCD29+ and unsorted 
HSC-3 cells were cultured for 12 hours and then treated with either vehicle control 
(DMSO) or ICG-001 for 24 hours. Untreated CD44+CD24highCD29+ cells showed rapid 
growth and metastasis within the first 2 hours following injection. This was in sharp 
contrast to CD44+CD24lowCD29+ cells and unsorted cells, which produced smaller 
tumors with no detectable metastases until 24 hours post-transplantation (Figure 39). 
Significantly, at 24 hours ICG-001 treatment abolished metastasis of 





proposed role in targeting β-catenin activity in immature cancer cells. Thus, inhibition 
of nuclear β-catenin activity by treatment with ICG-001 virtually eliminated metastasis 
of CD44+CD24highCD29+ cells in zebrafish embryos, confirming that β-catenin 
transcriptional activity was critical for the maintenance of aggressive human OSCC 
CSCs in vivo.  
 
Figure 41. Subpopulations of CD44+CD24highCD29+ and CD44+CD24lowCD29+ cells 
were isolated by FACS, grown in culture for 12 hours followed by treatment with either 
DMSO (vehicle) control or ICG-001 for 24 hours. Unsorted HSC-3 cells were used as 
control. Immunofluorescence imaging of tumor xenografts derived from unsorted RFP 
HSC-3 cells, RFP CD44+CD24lowCD29+ cells or CD44+CD24highCD29+ cells revealed 
that only CD44+CD24highCD29+ cells formed tumors that metastasized rapidly within 
2 hours to the tail and craniofacial regions (left panel)(n=3, unpaired t-test; **p<0.002, 
Anova; ***p<0.0002) . After 24 hours, metastases were detected from tumors derived 
from CD44+CD24highCD29+ as well as unsorted cells, and to a much lesser extent, from 
CD44+CD24lowCD29+ cells (middle panel). We note that a substantial population of 
zebrafish injected with CD44+CD24highCD29+ cells died within the 24 hours (middle 





001 inhibited tumor growth and abrogated metastases (right panel). N=6 unsorted and 
sorted low, n=5 sorted high vehicle, n=11 sorted high ICG-001, unpaired t-test; 
****p<0.0001, Anova; ****p<0.0001. 
 
β-catenin transcriptional activity is associated with tumor progression and patient 
survival in primary human OSCC 
To align β-catenin activity with a clinically aggressive OSCC, we assessed the 
derived ICG-001-inhibited gene expression profile in primary human OSCC samples 
by querying RNASeqdata from TCGA. The set of transcripts significantly down-
regulated with treatment in HSC-3 cells were projected onto the TCGA OSCC sample 
cohort (n=352) using ASSIGN (100). Samples were scored based on the coordinated 
expression of the gene signature, which, in turn, reflected the level of potential ICG-
001 inhibition (hereafter referred to as the ICG-001 inhibition score) per sample (Figure 
40A). We next performed survival analysis to test whether ICG-001 inhibition scores 
were predictive of patient outcome, using overall survival (OS) estimates for OSCC 
patients with paired ICG-001 inhibition scores (n=318). Comparison of the survival 
curves corresponding to patients with high (> median) or low (≤ median) ICG-001 
inhibition scores showed a significantly lower OS in the former group (Figure 40B; P 
= 0.031, log-rank test), with median survival estimates of 2.96 and 4.71 years in the 
high and low groups, respectively. This confirmed that the ICG-001 inhibition signature 
was predictive of patient prognosis in OSCC and suggested that patients with high 







Figure 42A &B. (A). Stratification of human OSCC samples using ICG-001 treatment 
gene expression signature from HSC-3 cells. The set of ICG-001 down-regulated genes 
(n=1,238) in HSC-3 cells were projected onto the TCGA OSCC RNASeq dataset 
(n=352) using ASSIGN. The heatmap of the signature expression profile (displayed as 
row z-scores of log-2 expression values per gene) is shown, with the estimated ICG-
001 inhibition ASSIGN scores highlighted above (purple). (B). Overall patient survival 
curves with respect to ICG-001 inhibition score. OSCC patients with survival 
information (n=318) were first divided into two groups: ICG-001 high and low, n = 159 
each based on the median ICG-001 inhibition scores and compared for their overall 
survival outcomes. Samples with higher ICG-001 inhibition scores had a lower overall 
survival, with median survival estimates of 2.96 and 4.71 years in the high and low 
groups, respectively. Statistical significance of survival difference between groups was 
determined using a log-rank test. 
 
Furthermore, comparison of the ICG-001 inhibition scores in OSCCs (n=320) 
versus cytologically normal adjacent epithelial (AE) samples (n=32) yielded 
significantly higher scores in OSCCs than in AE’s (Figure 41A; P = 4.3e-11, two-tailed 
t-test), thus showing that ICG-001 inhibition is associated with tumor status. We then 
looked at samples with known tumor grade information (n=311) to determine the 
association between ICG-001 inhibition scores and tumor progression. Remarkably, 





grade (Figure 41B; combined P = 2.21e-4), suggesting a correlation with tumor 
progression. Taken together, these results show that higher inhibition scores in primary 
tissues are associated with tumor status and positively associated with tumor 
progression, and suggest that more aggressive/advanced tumors are likely to be more 
responsive/susceptible to inhibition by ICG-001. 
 
 
Figure 43A &B. (A) ICG-001 inhibition scores with respect to OSCC tumor status. 
OSCC samples (n=320) have significantly higher ICG-001 inhibition scores than 
adjacent normal epithelia (AE) (n=32). Statistical significance was determined using 
an unpaired t-test comparing the two groups. (B) OSCC samples with known tumor 
grade status (n=311) were used to analyze the association of ICG-001 inhibition scores 
and tumor progression. A significant positive association was observed between ICG-
001 inhibition scores and increasing tumor grade. Statistical significance of the 
association of the ICG-001 inhibition scores with respect to tumor grade was 














ICG-001 inhibits N-glycosylation by downregulating GPT protein levels in HNSCC 
tumor xenografts in nude mice 
 
Examination of the ICG-001-inhibition gene signature did not reveal significant 
downregulation of the DPAGT1 transcript levels, suggesting that in the context HSC-
3 cells, it was not a direct target of β-catenin/CBP activity. However, we found that 
UAP1, the gene encoding UDP-N-acetyl-glucoseamine pyrophosphorylase 1 that 
functions at the last step in the hexosamine pathway to generate UDP-GlcNAc, a 
substrate for GPT, was downregulated >2-fold (data not shown). To assess if DPAGT1 
was affected by ICG-001 on the level of GPT expression, we examined its abundance 
in tumor xenografts from mice treated with ICG-001 compared to the vehicle control 
(Figure 42). Strikingly, immunofluorescence staining of GPT in ICG-001 treated 
tumors was reduced, suggesting that ICG-001 impacted DPAGT1 on a post-




Figure 44. A. Immunofluorescence imaging of GPT in OSCC tumor xenografts shows 
that ICG-001 inhibits GPT abundance. B. GSEA plot corresponding to ICG-001 
inhibition scores in TCGA OSCC data for gene sets pertaining to DPAGT1 knockdown 
in HSC-3 cells. Genes that are down-regulated are enriched towards higher ICG-001 
inhibition levels, while genes that are up-regulated are enriched towards lower ICG-
001 inhibition levels, suggesting ICG-001 inhibition is positively correlated with 






To better understand the contribution of DPAGT1 to OSCC in the context of β-
catenin/CBP activity and ICG-001 inhibition, we used additional computational 
methods to determine whether there was an overlap between DPAGT1 activated and 
ICG-001 inhibited (i.e. β-catenin/CBP activated) genes. Given that our previous studies 
provided evidence for a cross talk between β-catenin signaling and DPAGT1 
expression, and given that DPAGT1 activity and ICG-001 inhibition signature track 
with advanced OSCC, we hypothesized that a subset of pro-tumorigenic genes and 
pathways will be sensitive to both, ICG-001 and the GPT inhibitor, tunicamycin. Thus, 
we utilized the Connectivity Map (https://www.broadinstitute.org/connectivity-map-
cmap) using gene inhibition signature derived using a third generation β-catenin/CBP 
inhibitor, E7386 (PENT) (a gift from Eisai, Inc.) with HSC-3 cells.  First, to validate 
that E7386 inhibitory activity paralleled that of ICG-001, we determined the correlation 
coefficient r that measures the strength and direction of a linear relationship between 
these two compounds in TCGA OSCC. Shown in Figure 43 is a scatterplot 








Figure 45. E7386 inhibition scores are highly correlated to ICG-001 inhibition scores 
in TCGA OSCCs. 
We next queried the c-map – a portal that allows to query a treatment gene 
expression signature of interest against thousands other annotated treatment signatures 
in order to assess if they have mimicking or antagonizing effects across multiple 
cellular contexts. Upon interrogating our derived E7386 treatment signature in HSC-3 
cells in this manner, tunicamycin was ranked highly out of the total ~ 476,000 entries, 
highlighting that there was significant overlap between transcriptional signatures of 
ICG-001 and inhibition of DPAGT1/GPT with tunicamycin (Figure 44). Therefore, by 









Figure 46. Connectivity Map query for (anti)correlative effects with E7386 treatment. 
Tunicamycin (specific inhibitor of GPT) signature from the c-map shows overlap 


















Section 2: Wnt/β-catenin in HNSCC Highlights 
 
• Disruption of the interaction between nuclear β-catenin and CBP with a small 
molecule inhibitor, ICG-001, abrogated cell proliferation and mesenchymal 
cell phenotypes while enhancing E-cadherin adhesion in cellular models of 
HNSCC.  
• ICG-001 inhibited HNSCC tumor growth and invasive phenotypes in nude 
and syngeneic mouse models, concomitant with enhanced intercellular 
adhesion.  
• Inhibiting β-catenin/CBP activity preferentially targeted the ability of 
subpopulations of stem-like cells to establish metastatic tumors in zebrafish. 
• Interrogation of the association between ICG-001 inhibition gene expression 
signatures and clinical features of HNSCC patients in TCGA revealed that the 
β-catenin/CBP transcriptional activity tracked with tumor grade and poor 
overall patient survival.   
• Aberrant activation of the β-catenin/CBP axis promoted aggressive traits of 
HNSCC; targeting the β-catenin/CBP interaction in the nucleus may provide 











A central challenge to understanding cancer biology on a tissue level is to 
decode how functions of specific proteins and pathways are regulated and coordinated 
to drive disease. On a biological level, changes in cell phenotype between epithelial 
and mesenchymal states, collectively termed as EMT, play a pivotal role in the 
pathogenesis of cancer by conferring on epithelial cells new traits required for tumor 
initiation and progression to advanced disease. EMT is a complex molecular and 
cellular program by which epithelial cells shed their differentiated characteristics, 
including cell–cell adhesion, planar and apical–basal polarity and acquire mesenchymal 
features, including motility, invasiveness and an enhanced resistance to apoptosis. The 
profound changes associated with EMT are mediated by multitude of signals in the 
epithelium and the stroma and they underlie epithelial cell plasticity and contribute to 
tumor progression and intra-tumoral heterogeneity.  
Loss of E-cadherin-mediated cell-cell adhesion coincident with acquisition of 
motility represents a central feature of EMT. Inhibition of E-cadherin adhesion has been 
shown to be associated with aberrant activation of Wnt/β-catenin signaling with these 
two processes being interdependent. We have shown previously that aberrant 
upregulation of DPAGT1 in OSCC led to an unchecked amplification of a positive 
feedback loop with canonical Wnt signaling, leading to hyper-glycosylation of E-
cadherin and loss of epithelial cell-cell adhesion. Although their dysregulation has been 
linked to cancer and EMT for many years, the mechanisms remain incompletely 





In this study, we provide evidence for an important role of the metabolic 
pathway of protein N-glycosylation and its evolutionarily conserved key regulator, the 
DPAGT1 gene, in promoting EMT. We show that high DPAGT1 expression is OSCC 
cells and OSCC tumors in TCGA segregates with mesenchymal phenotypes, EMT and 
advanced disease. Further, DPAGT1 expression and mesenchymal characteristics of 
metastatic HSC-3 cells correlate with increased modification of cell surface proteins 
with complex N-glycans. Knockdown of DPAGT1 in these cells results in 
downregulation of the EMT-specific genes. Specifically, DPAGT1 has the ability to 
induce transcription factors that orchestrate EMT programs and impart aggressive traits 
involving loss of E-cadherin adhesion, upregulation of β-catenin levels and acquisition 
of motility. EMT transcription factors have been demonstrated to be capable of 
orchestrating EMT programs during cancer development and progression (107). 
Among them, ZEB1 is a major driver of EMT that we find to be most impacted by 
forced expression of DPAGT1 and whose expression levels in OSCC TCGA track with 
DPAGT1 activity score. We show that indolent OSCC CAL27 cells lose their epithelial 
characteristics in response to ectopic expression of DPAGT1 by upregulating ZEB1 
along with other EMT transcription factors, TWIST1,2 and SNAI2. The significance 
of concomitant upregulation of ZEB1 and SNAI2 by DPAGT1 is unclear, although it 
may reflect their activities in subpopulations of OSCC cells that underlie cellular and 
tissue heterogeneity. Alternatively, these core regulators of EMT may also function in 
a network through which they co-regulate tumor progression. In addition, 
overexpression of DPAGT1 induced expression of mesenchymal proteins, vimentin, 
fibronectin and N-cadherin. Such dramatic upregulation of these important EMT 





glycosylation modulates cell plasticity and that it drives a switch between epithelial to 
mesenchymal states in OSCC (19, 107, 108).  
  By interrogating the DPAGT1 ‘activity score’ in OSCC specimens in the TCGA 
we provide in silico validation of our findings while highlighting additional oncogenic 
activities associated with DPAGT1. Collectively, our data show that through its control 
of cellular N-glycosylation, DPAGT1 imposes a previously unrecognized layer of 
cellular control and that its aberrant activation induces oncogenic activities (108).   
Current understanding is that the EMT program can be triggered by a diverse 
set of stimuli including growth factor signaling, such as TGF-β, Wnt signaling, tumor–
stromal cell interactions, and hypoxia, among others. The relative importance of each 
of these signals may depend on the cellular context. The present study reveals that 
another unique way to induce EMT is through overexpression of DPAGT1, a key 
regulator of protein-N-glycosylation. This is consistent with previous report by Pinho 
SS (107).  
Our studies provide a mechanistic link between DPAGT1 and Wnt/β-catenin 
signaling with the evidence that DPAGT1 inhibits the activity of GSK3β. Inhibition of 
GSK3β activity by phosphorylation at Ser9 is strongly associated with tumorigenesis, 
in part, through stabilization of EMT transcription factors SNAIL1, SNAI2 and ZEB1. 
All three factors are targets of GSK-3β mediated phosphorylation, followed by 
ubiquitination and proteosomal degradation. SNAILs function as transcriptional 
repressors of E-cadherin by binding to its promoter. Thus, reduced GSK3β activity may 
be responsible for elevated ZEB1 and SNAIL levels and inhibition of E-cadherin 





interactions between E-cadherin and γ-catenin. Thus, in subpopulations of OSCC 
tumors where E-cadherin expression is not lost, its adhesive activity is inhibited by 
extensive N-glycosylation due to high DPAGT1 levels.  
Although not discussed here, hyper-enrichment analysis of DPAGT1 activity 
revealed that it was highly enriched in EGFR and AKT pathways, as well as in NRF2 
and AP1 transcription factors. EGFR belongs to a class of high multiplicity N-
glycosylated proteins, with N-glycosylation playing a major role in its retention at the 
cell surface and activation of pro-tumorigenic signaling. EGFR is a major driver of 
OSCC, being upregulated in >90% of tumors in the absence of genomic alterations. 
Since AKT is a downstream target of EGFR, its enrichment in DPAGT1 gene 
signatures may be directly related to EGFR activity (109).   
We found that some of the top-ranked DPAGT1 targets included N-
glycosylation genes, GALT and FUT11 and several sialyltransferases, although the 
effects of DPAGT1 differed depending on the gene, and the significance of these 
specific N-glycosylation-enzyme driven modifications is unclear. FUT11 has been 
implicated as a potential biomarker of clear cell renal cell carcinoma progression. 
Lastly, an interesting new finding from these in silico analyses of DPAGT1-activated 
genes involves the identification of epigenetic regulators of chromatin structure 
HDAC1 and PCAF. Since β-catenin has been shown to be stabilized by PCAF-
mediated acetylation, DPAGT1 is also likely to impact its Wnt/β-catenin activity on 
epigenetic levels through its effects on PCAF gene expression.   
The role of Wnt/β-catenin signaling in tumorigenesis has been acknowledged 





understood (52). In addition to serving as a major mediator of canonical Wnt signals 
and a structural component of cadherin junctions, β-catenin plays critical roles in a 
plethora of cellular functions such as cytoskeletal dynamics, cell division and as a 
regulator of apoptosis (39). Because of these complex functions in homeostasis and 
tissue renewal, targeting β-catenin has been controversial. Most recent studies have 
highlighted the importance of inhibiting the nuclear function of β-catenin downstream 
of the Axin/GSK3β destruction complex, thus intercepting its oncogenic nuclear 
activities while allowing it to participate in different homeostatic processes (79, 110). 
Here, we show that a small molecule inhibitor of nuclear β-catenin-CBP interaction, 
ICG-001, abolishes OSCC cell proliferation and drives an epithelial phenotype, in part, 
by promoting membrane localization of β-catenin without affecting β-catenin transcript 
or protein levels. In mouse models of tongue OSCC, ICG-001 inhibits invasive tumor 
growth and promotes a capsular phenotype. Further, ICG-001 abrogates the ability of 
subpopulations of cells with stem-like aggressive properties to induce rapid tumor 
formation and metastases in zebrafish. Our analysis of the effectors of ICG-001 
treatment of a panel of OSCC cell lines displaying different invasive properties showed 
a dose-dependent growth inhibition that is inversely related to nuclear β-catenin 
abundance, with aggressive HSC-3 harboring high nuclear β-catenin and exhibiting the 
lowest EC50 value, and CAL27 cells with less nuclear β-catenin being least sensitive.  
Microarray analyses of global transcriptome and protein expression analyses 
from CAL27 and HSC-3 cells in response to the ICG-001 treatment did not reveal any 
significant changes in either β-catenin transcriptional expression or protein abundance. 





the role of ICG-001 in inhibiting β-catenin-CBP interaction rather than its 
transcriptional abundance or protein stability. These studies suggest a shift to p300 and 
differentiation program. Notably, we also show that the coordinated activity/expression 
level of ICG-001-inhibited transcripts stratifies primary tissue samples by their 
prognosis and identifies patients likely to respond to the inhibitor.  Collectively, our 
results suggest that OSCC cells, and aggressive OSCC cells in particular, rely on β-
catenin activity and that targeting β-catenin activity may offer promise for the therapy 
of OSCC.    
The interplay between Wnt/β-catenin signaling and E-cadherin adhesion has 
been shown to regulate the epithelial phenotype by affecting cell polarity, cytoskeletal 
dynamics and EMT (47). As a structural component of E-cadherin junctions, β-catenin 
plays key roles in intercellular adhesion. In response to ICG-001 treatment, the OSCC 
cell lines and orthotopic murine xenografts displayed enhanced β-catenin focused 
localization at the cell membrane coincident with increased E-cadherin abundance and 
junctional localization. Similar effect of ICG-001 was also detected in a murine tumor 
immunocompetent model, providing evidence that ICG-001 inhibits aggressive 
properties in SCC irrespective of the immune microenvironment (111).  
Aberrantly high Wnt/β-catenin activity has been shown to be associated with a 
niche of aggressive HNSCC cells with stem-like properties, enabling them to initiate 
rapidly growing new tumors that progress to produce early lymphogenic metastases 
and to have a poor prognosis through an epigenetic mechanism involving interaction 
among β-catenin, MLL and CBP (74). These aggressive stem-like cells were shown to 
express N-glycoprotein surface markers characteristic of stem cells, CD44, CD24, and 





embryonic zebrafish as a model, we show that a subset of OSCC CD44+CD24highCD29+ 
cells rapidly metastasizes in contrast to unsorted cells or cells expressing low levels of 
the CD24 marker. Further, pretreatment of these cells with ICG-001 that targets β-
catenin-CBP interaction inhibited their ability to grow and metastasize without 
impacting their viability, suggesting that aggressive OSCC subpopulations require the 
β-catenin-CBP axis for survival and function. These results provide evidence that ICG-
001 inhibits OSCC stem-like cell population in its ability to grow aggressive tumors in 
zebrafish. 
Our studies also reveal that ICG-001 gene signatures derived from differential 
gene expression testing were cell type-specific with a significantly larger number of 
changes found in more aggressive HSC-3 cells than in indolent CAL27 cells. One 
possible explanation is that aggressive HSC-3 cells utilize more cellular processes that 
depend on the β-catenin-CBP axis activity than non-metastatic CAL27 cells. We have 
demonstrated before that two Hippo signaling effectors, YAP and its paralog TAZ, are 
associated with OSCC with their transcriptional activities tracking with disease 
development and progression to aggressive state (103). GSEA of the YAP/TAZ-
associated signature revealed a positive correlation between ICG-001 treatment and 
YAP/TAZ knockdown in HSC-3 cells suggesting potential convergence of β-catenin 
with YAP/TAZ in OSCC, as observed in other cancers (112).  
In addition to interacting with TCF/LEF, nuclear β-catenin partners with many 
other transcription factors, including FOXO, SOX, SMAD, HIF1α and YAP/TAZ, 
indicating that standard gene reporter assays such as TOP-FLASH for β-catenin activity 
are not likely to reveal the spectrum of its functions. Indeed, GSEA revelaed that a 





YAP/TAZ are major effectors of the Hippo pathway and they act as potent oncogenic 
factors by promoting proliferation, survival, and stemness. Indeed, all these activities 
are ihhibited by ICG-001, suggesting that β-catenin/CBP also interact with YAP/TAZ 
on a transcriptional level. Since we have shown that YAP/TAZ are major players in the 
pathobiology of OSCC (103), these results suggested that β-catenin/CBP signaling 
converge with YAP/TAZ and that ICG-001 may effectively inhibit both oncogenic 
activities. 
To obtain a better insight into the effects of ICG-001 on β-catenin 
transcriptional activity, we turned to computational methods to uncover gene 
expression signatures of ICG-001 and align them with β-catenin pathway activities. We 
previously highlighted the power of integrating in vitro treatment signatures with large 
multi-omic data made available through consortia such as the TCGA network in order 
to further dissect their importance in primary human malignancies (103). Here, we 
applied these integrative approaches to interrogate ICG-001 inhibition in OSCC in 
order to draw meaningful conclusions on the patho-clinical relevance of the in vitro 
treatment signature derived from aggressive HSC-3 OSCC cells. By projecting the set 
of down-regulated genes onto TCGA OSCC RNASeq data, we were first able to obtain 
estimates of ICG-001 inhibition scores across all samples, with the inhibition scores 
reflecting the overall expression levels of the entire gene set. Survival analysis revealed 
that patients in which the ICG-001 inhibited genes were overexpressed (i.e. patients 
with higher ICG-001 inhibition scores) showed a significantly worse prognosis, in turn 
suggesting that treatment of these patients with ICG-001 may indeed improve their 
overall survival. Additionally, ICG-001 inhibition scores were found to be significantly 





tumor grade, highlighting that more aggressive OSCCs characterized by a less 
differentiated state, may indeed be more sensitive to ICG-001 treatment.  
The ICG-001 gene expression signature did not include DPAGT1, suggesting 
that DPAGT1 was not a direct target of β-catenin/CBP in HSC-3 cells. However, we 
find that GPT is downregulated in ICG-001-treated OSCC tumor xenografts. Given that 
the UAP1 gene is downregulated upon ICG-001 treatment, it is likely that, in the HSC-
3 context, the DPAGT1 protein, GPT, is impacted on a post translational level by 
limited substrate availability due to inhibition of UAP1 expression. Since the GPT 
inhibitor, tunicamycin, targets oncogenic pathways with signatures that overlap ICG-
001, these collective findings suggest that β-catenin/CBP and DPAGT1/N-
glycosylation converge and that by inhibiting β-catenin/CBP signaling ICG-001 also 
targets DPAGT1/N-glycosylation.   
To date, OSCC remains a devastating disease that poses a major global health 
problem (2, 113). Current clinical management of this malignancy remains limited by 
factors such as treatment-associated morbidity, resistance to radiotherapy, and disease 
persistence/recurrence (114). Decoding the underlying molecular mechanisms involved 
in OSCC development and progression to aggressive disease is critical to the discovery 
of new druggable targets and novel effective treatment regimes. Using cellular and 
animal models, as well as human data, we highlight the contribution of the β-
catenin/CBP signaling axis and DPAGT1/N-glycosylation to OSCC and provide 
evidence that targeting β-catenin/CBP may be a useful strategy to intercept this 
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